<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Med Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Med Oncol</journal-id><journal-title-group><journal-title>Medical Oncology (Northwood, London, England)</journal-title></journal-title-group><issn pub-type="ppub">1357-0560</issn><issn pub-type="epub">1559-131X</issn><publisher><publisher-name>Springer US</publisher-name><publisher-loc>New York</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40407951</article-id><article-id pub-id-type="pmc">PMC12102098</article-id>
<article-id pub-id-type="publisher-id">2765</article-id><article-id pub-id-type="doi">10.1007/s12032-025-02765-7</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>The role of the tumour microenvironment in lung cancer and its therapeutic implications</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Edirisinghe</surname><given-names>Devindi Thathsara</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kaur</surname><given-names>Jasleen</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Yue Qi</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lim</surname><given-names>Huey Xin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lo</surname><given-names>Sharis Wan Ting</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Vishupriyaa</surname><given-names>Sri</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Tan</surname><given-names>Ee Wern</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Wong</surname><given-names>Rebecca Shin Yee</given-names></name><address><email>rebeccaw@sunway.edu.my</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Goh</surname><given-names>Bey Hing</given-names></name><address><email>goh.beyhing@uts.edu.au</email><email>beyhingg@sunway.edu.my</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04mjt7f73</institution-id><institution-id institution-id-type="GRID">grid.430718.9</institution-id><institution-id institution-id-type="ISNI">0000 0001 0585 5508</institution-id><institution>Department of Medical Education, Sir Jeffrey Cheah Sunway Medical School, Faculty of Medical and Life Sciences, </institution><institution>Sunway University, </institution></institution-wrap>No. 5 Jalan Universiti, 47500 Petaling Jaya, Selangor Darul Ehsan Malaysia </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04mjt7f73</institution-id><institution-id institution-id-type="GRID">grid.430718.9</institution-id><institution-id institution-id-type="ISNI">0000 0001 0585 5508</institution-id><institution>Sunway Biofunctional Molecules Discovery Centre, Faculty of Medical and Life Sciences, </institution><institution>Sunway University, </institution></institution-wrap>No. 5 Jalan Universiti, 47500 Petaling Jaya, Selangor Darul Ehsan Malaysia </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03f0f6041</institution-id><institution-id institution-id-type="GRID">grid.117476.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7611</institution-id><institution>Faculty of Health, Australian Research Centre in Complementary and Integrative Medicine, </institution><institution>University of Technology Sydney, </institution></institution-wrap>Ultimo, Australia </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05031qk94</institution-id><institution-id institution-id-type="GRID">grid.412896.0</institution-id><institution-id institution-id-type="ISNI">0000 0000 9337 0481</institution-id><institution>Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, </institution><institution>Taipei Medical University, </institution></institution-wrap>Taipei, Taiwan </aff></contrib-group><pub-date pub-type="epub"><day>23</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>23</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>42</volume><issue>6</issue><elocation-id>219</elocation-id><history><date date-type="received"><day>6</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>28</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Lung cancer is the leading cause of cancer-related deaths globally, with tumour growth, invasion, and treatment response heavily influenced by the tumour microenvironment (TME). The TME promotes tumour progression by creating an immunosuppressive environment that hampers the body&#x02019;s antitumour immune response, primarily through the Nuclear Factor Kappa B (NF-&#x003ba;B) and Signal Transducer and Activator of Transcription 3 (STAT3) pathways. These pathways contribute to chronic inflammation, immune evasion, and angiogenesis. Targeting the TME and its signalling pathways has shown potential to enhance treatment efficacy. STAT3, a key transcription factor in lung cancer, drives tumour growth and immune suppression via the mTOR and JAK pathways. Inhibiting these pathways can block STAT3 and slow cancer progression. Promising results have been observed with mTOR inhibitors like CC-115 and Vistusertib, especially when combined with immune checkpoint inhibitors, and with JAK inhibitors such as Ruxolitinib, AZD4205, and Filgotinib. These strategies represent a promising direction for lung cancer therapy. This review explores the intricate relationship between the TME and lung cancer, focussing on novel therapeutic approaches that target immune cells, signalling molecules, and fibroblasts within the TME to improve patient outcomes.</p><sec><title>Graphical abstract</title><p id="Par2">Overview of the lung TME, illustrating key cellular components, signalling pathways, and their roles in tumour proliferation, metastasis, immune evasion, and angiogenesis.
<graphic position="anchor" xlink:href="12032_2025_2765_Figa_HTML" id="MO1"/></p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Tumour microenvironment</kwd><kwd>Therapeutic implications</kwd><kwd>Lung cancer</kwd><kwd>NF-&#x003ba;B pathway</kwd><kwd>STAT3 pathway</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100010798</institution-id><institution>Sunway University</institution></institution-wrap></funding-source><award-id>GRTIN-ECR-SBMDC-05-2024</award-id><award-id>GRTIN-RAG-SBMDC-10-2024</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>University of Technology Sydney</institution></funding-source></award-group><open-access><p> Open Access funding enabled and organized by CAUL and its Member Institutions</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Science+Business Media, LLC, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par58">Bronchogenic carcinoma, also known as lung cancer, occurs due to the development of tumours within the bronchial airways or the parenchyma and has the highest mortality rate for cancer-related deaths globally [<xref ref-type="bibr" rid="CR1">1</xref>]. The two main types of lung cancer are Non-Small Cell Lung Cancer (NSCLC), accounting for 85% of cases, and Small Cell Lung Cancer (SCLC), accounting for 15% of cases, despite its extremely aggressive nature. The late diagnosis of lung cancer at advanced stages leads to the limited available treatment options. Therefore, early detection along with improved therapeutic strategies is extremely crucial to increase the patient survival rates [<xref ref-type="bibr" rid="CR2">2</xref>].</p><p id="Par59">In the past decade, the considerable influence of TME on the onset and advancement of primary de novo lung carcinoma has been gaining substantial recognition. The TME is a complex microenvironment that plays a key role in tumour growth, metastasis, and therapeutic intervention response. TME consists of cellular and non-cellular factors, such as the stromal cells, immune cells, signalling molecules and the extracellular matrix, which interact with one another thereby regulating the tumour behaviour. Recent research has revealed that the composition of immune cells within the tumour environment influences the prognosis of lung cancer in patients [<xref ref-type="bibr" rid="CR3">3</xref>].</p><p id="Par60">In inflammatory conditions such as chronic obstructive pulmonary disease (COPD), the lung TME exhibits features that may facilitate carcinogenesis. The human lung adenocarcinoma displays a range of subtypes, where each are defined by distinct cellular and mutational heterogeneity. Notably, this heterogeneity is not limited to the tumour epithelial cells and could extend beyond to encompass the TME, which includes the vasculature, cancer-associated fibroblast (CAFs), extracellular matrix (ECM), and infiltrating immune cells. In NSCLC, the degree of immune cell infiltration is dependent on the disease stage, suggesting that the lung TME influences carcinogenesis and may serve as a prognostic factor. Consequently, specific TME profiles are under investigation to be used as potential biomarkers for assessing disease stage and subtype along with predicting clinical outcomes and guiding therapeutic strategies [<xref ref-type="bibr" rid="CR4">4</xref>].</p><p id="Par61">The TME also consists of a vast array of immune cells such as myeloid-derived suppressor cells, tolerogenic dendritic cells, tumour-associated macrophages and regulatory T cells. The accumulation of these cells results in an immunosuppressive environment thereby, hindering the antitumour immune response of the body. This is one of the key reasons why targeting the TME is crucial for improving treatments for lung cancer [<xref ref-type="bibr" rid="CR5">5</xref>]. Hence, this literature review aims to explain the extensive roles of the TME in lung cancer, primarily focussing on the immunosuppressive cells, cancer-related fibroblasts and identifying therapeutic strategies that could enhance treatment efficacy and patient outcomes.</p></sec><sec id="Sec2"><title>TME and its mechanisms</title><sec id="Sec3"><title>TME</title><p id="Par62">The metabolic exchange of substances (such as nutrients and oxygen) is not only essential for the survival of normal lung cells but is also crucial in maintaining the lung TME to enhance malignant cell growth. The TME plays a crucial role in the growth and metastasis of lung cancer. It consists of a heterogenous mixture of cell populations, including cancer cells, stromal cells, blood vessels, immune cells, signalling mediators and extracellular matrix proteins. The environment of chronic inflammation in TME contributes to altered immune cell differentiation and hinders antitumour activity, ultimately increasing tumour evasion [<xref ref-type="bibr" rid="CR6">6</xref>]. Therefore, the TME can potentially be used in prognostics of NSCLC for determining the stage, clinical outcomes, and response to therapy [<xref ref-type="bibr" rid="CR4">4</xref>].</p><p id="Par63">In addition, chronic inflammation within the TME is driven by various cytokines, chemokines, and other signalling molecules that shape the tumour microenvironment and promote tumour progression. These factors create an immune-evasive environment, facilitating cancer cell survival, invasion, and metastasis [<xref ref-type="bibr" rid="CR7">7</xref>]. An example of a cytokine involved in the TME and implicated in the progression of lung cancer is interleukin 8 (IL-8). Research has shown that CAFs are activated by lactate produced by tumour cells, leading to increased secretion of IL-8 [<xref ref-type="bibr" rid="CR8">8</xref>].</p><p id="Par64">Besides chronic inflammation, vessel co-option also plays a role in tumourigenesis and responses to therapies. Vessel co-option refers to a non-angiogenic process where cancer cells utilize pre-existing blood vessels for vascularization instead of inducing new vessel formation. It has been observed across various tumour types, including primary and metastatic lung cancer. Importantly, vessel co-option is now implicated as a major mechanism mediating resistance to conventional anti-angiogenic drugs, potentially explaining their limited efficacy in treating advanced-stage/metastatic lung cancer, in adjuvant settings, and for primary lung tumours. Vessel co-option may influence responses to anti-angiogenic and immunotherapies in lung cancer and suggests a need for therapies targeting both angiogenesis and vessel co-option [<xref ref-type="bibr" rid="CR9">9</xref>].</p><p id="Par65">On the other hand, serglycin (SRGN), a factor within the lung TME secreted by both tumour and stromal cells, promotes NSCLC aggressiveness. This occurs through its interaction with the CD44 receptor on NSCLC cells, leading to increased cell migration, invasion, and colonization. SRGN also induces stem-like properties, enhances resistance to chemotherapy and anoikis, and promotes epithelial-mesenchymal transition (EMT). Notably, increased SRGN expression is associated with poorer prognosis in lung adenocarcinoma, highlighting its significant role in driving lung cancer progression [<xref ref-type="bibr" rid="CR10">10</xref>].</p></sec><sec id="Sec4"><title>NF-&#x003ba;B and STAT3 pathways involved in the lung TME</title><p id="Par66">Cytokines are crucial components that contribute to chronic inflammation, which is linked to cancer. It also enhances the formation of malignant cells, promotion of metastasis and immune cell evasion. There are several inflammatory pathways involved in the maintenance of TME in lung cancer. Two of the main pathways are NF-&#x003ba;B and STAT3, which can be activated by cytokines, leading to cellular gene damage and mutations, ultimately resulting in tumour development. Moreover, these pathways also increase inflammatory factor production to upkeep the TME and contribute to inflammation and the tumour cycle [<xref ref-type="bibr" rid="CR11">11</xref>]. The resulting production of inflammatory factors creates a vicious cycle, supplying signals for inflammatory pathways, and therefore further production of cytokines. Some of the inflammatory factors involved in lung cancer are IL-6, IL-11, IL-12 and TNF-&#x003b1;.</p><p id="Par67">The overactivation of NF-&#x003ba;B pathway causes increased cell survival, vascularisation, and cell invasion, all of which are factors that lead to development of cancer. Additionally, NF-&#x003ba;B inhibits apoptosis through several mechanisms, including the degradation or inhibition of caspases and the induction of inhibitors of apoptosis&#x000a0;(IAPs) [<xref ref-type="bibr" rid="CR12">12</xref>]. Hence, as NF-&#x003ba;B has strong correlations to the inflammation of tumours, studies have showed that as NF-&#x003ba;B can function as a target for therapeutic strategies [<xref ref-type="bibr" rid="CR12">12</xref>]. The NF-&#x003ba;B pathway can be activated by cytokines such as TNF-&#x003b1;, IFN-&#x003b3; and IL-17, as well as oncogenes and tumour suppressors. After stimulation, the I&#x003ba;B kinase complex (IKK) phosphorylates I&#x003ba;B proteins, which are bound to NF-&#x003ba;B. This results in the degradation of I&#x003ba;B proteins by proteasomes, causing the release of NF-&#x003ba;B proteins [<xref ref-type="bibr" rid="CR13">13</xref>]. The signal transduction cascade ultimately enables the translocation of NF-&#x003ba;B complex into the nucleus, activating transcription of various inflammatory genes [<xref ref-type="bibr" rid="CR14">14</xref>]. Hence, the activation of NF-&#x003ba;B pathway is often present in the TME and cancer cells in most solid tumours.</p><p id="Par68">Signal transducer and activator of transcription 3 (STAT3) is a transcription factor that is constitutively activated in cancer cells and functions as an oncogene essential for carcinogenesis and tumour development. It regulates processes such as tumour cell survival, proliferation, invasion, and inflammation [<xref ref-type="bibr" rid="CR15">15</xref>]. STAT3 promotes angiogenesis through hypoxia-inducible factors (HIF) and vascular endothelial growth factor A (VEGFA). The knockdown of STAT3 has been shown to completely ablate the expression of hypoxia-inducible factor-1 &#x003b1; (HIF-1&#x003b1;), hypoxia-inducible factor-2 &#x003b1; (HIF-2&#x003b1;) and VEGFA, all of which are critical for angiogenesis [<xref ref-type="bibr" rid="CR16">16</xref>]. STAT3 is a downstream target of mechanistic target of rapamycin complex 1 (mTORC1) and is activated by cytokines or growth factors binding to cell surface receptors. Full activation of STAT3 requires phosphorylation at two sites: tyrosine 705 (Tyr705) and serine 727 (Ser727). When interleukin 6 (IL-6) binds to its cell surface receptor, it recruits and activate Janus kinase (JAK) family members, which phosphorylates STAT3 at Tyr705, facilitating nuclear translocation and enhancing cytokine-mediated gene expression. Additionally, mTORC1 directly phosphorylates STAT3 at Ser 727, driving cancer cell proliferation and the formation of large cancer cell clusters.</p><p id="Par69">Importantly, aberrant STAT3 signalling through pathways such as VEGFA not only drives tumour growth but also contributes to drug resistance by promoting a tumour-supportive microenvironment, enhancing cancer cell survival, and impairing therapeutic efficacy. Drug resistance remains a major challenge in cancer therapy, often arising from both intrinsic and acquired mechanisms, including genetic mutations, epigenetic alterations, cancer stem cell plasticity, and exosome-mediated communication, all of which contribute to treatment failure and disease progression [<xref ref-type="bibr" rid="CR17">17</xref>]. Taken together, the roles of cytokines, NF-&#x003ba;B, and STAT3 in cancer development and TME regulation is tabulated in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> and illustrated in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> below.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Roles of cytokines, NF-&#x003ba;B, and STAT3 in cancer development and TME regulation</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Cytokine/Pathyway</th><th align="left">Key findings</th><th align="left">Reference</th></tr></thead><tbody><tr><td align="left">Cytokines</td><td align="left"><p>&#x02022; Promote chronic inflammation and tumour growth</p><p>&#x02022; Enhance metastasis and immune evasion</p><p>&#x02022; Activate NF-&#x003ba;B and STAT3 pathways</p><p>&#x02022; Sustain TME via IL-6, IL-11, IL-12, TNF-&#x003b1;</p></td><td align="left">[<xref ref-type="bibr" rid="CR11">11</xref>]</td></tr><tr><td align="left">NF-&#x003ba;B</td><td align="left"><p>&#x02022; Increases cell survival, angiogenesis, invasion</p><p>&#x02022; Inhibits apoptosis (blocks caspases, induces IAPs)</p><p>&#x02022; Activated by TNF-&#x003b1;, IFN-&#x003b3;, IL-17</p><p>&#x02022; IKK degrades I&#x003ba;B, freeing NF-&#x003ba;B to trigger inflammatory genes</p></td><td align="left">[<xref ref-type="bibr" rid="CR12">12</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref>]</td></tr><tr><td align="left">STAT3</td><td align="left"><p>&#x02022; Drives tumour growth, angiogenesis (HIF/VEGFA)</p><p>&#x02022; Activated by IL-6/JAK (Tyr705) and mTORC1 (Ser727)</p><p>&#x02022; Knockdown suppresses HIF-1&#x003b1;, HIF-2&#x003b1;, VEGFA</p><p>&#x02022; Promotes cancer cell proliferation and clustering</p></td><td align="left">[<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]</td></tr></tbody></table></table-wrap><fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Roles of different cells in the TME of lung cancer</p></caption><graphic xlink:href="12032_2025_2765_Fig1_HTML" id="MO2"/></fig></p></sec><sec id="Sec5"><title>Cells involved in the lung TME</title><p id="Par70">The overall effects of various cells within the TME are summarized in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>. Tumour-associated macrophages (TAMs) are key contributors to the TME, secreting inflammatory mediators that drive chronic inflammation. TAMs are broadly categorized into two types: M1 and M2 macrophages. M1 macrophages primarily produce IL-12 and IL-23, which are involved in pathogen destruction and tumour cell cytotoxicity. Conversely, M2 macrophages promote tumour stroma formation, tumour growth, metastasis, and angiogenesis. In the lung cancer TME, signalling pathways lead to an imbalance favouring a higher proportion of M2 macrophages over M1, thus promoting tumour progression and immune evasion [<xref ref-type="bibr" rid="CR18">18</xref>]. Additionally, macrophage activity is modulated by tumour cell transcription factors, such as NF-&#x003ba;B and STAT3. The interplay between these factors fosters a microenvironment conducive to cancer cell proliferation, inhibition of apoptosis, angiogenesis, extracellular matrix remodelling and metastasis.</p><p id="Par71">Myeloid-derived suppressor cells (MDSCs) are key regulators within the TME of lung cancer. MDSCs are immune precursor cells that contribute to immunosuppression and facilitate immune evasion by targeting the T cells. Additionally, MDSCs produce vascular endothelial growth factor (VEGF), which enhances tumour growth [<xref ref-type="bibr" rid="CR19">19</xref>]. Overexpression of VEGF leads to the formation of new blood vessels, supplying oxygen and nutrients to tumour cells, thereby promoting tumour invasion and metastasis [<xref ref-type="bibr" rid="CR20">20</xref>]. Studies have demonstrated a strong correlation between peripheral blood MDSC levels and tumour stage and metastasis, indicating that reducing MDSCs levels could inhibit tumour progression and metastasis [<xref ref-type="bibr" rid="CR19">19</xref>]. Elevated levels of MDSCs within the TME further enhance immunosuppression.</p><p id="Par72">The main immune cells that combat cancer are CD8<sup>+</sup> T cells and CD4<sup>+</sup> T cells. CD8<sup>+</sup> T cells kill cancer cells by migrating into the TME, differentiating into effector CD8<sup>+</sup> T cells, and then into cytotoxic and memory CD8<sup>+</sup> T cells. To accomplish this, external and internal transcription factors regulate the cell&#x02019;s surface receptors, induces multiplication, and produces effectors to kill the cancer cells within the TME. However, the normal immune functions of lung cancer patients may be impaired, as dysfunction of the CD8<sup>+</sup> T cells can occur [<xref ref-type="bibr" rid="CR21">21</xref>]. Conversely, accumulation of CD4<sup>+</sup> T cells such as Th2 cells and Tregs can be observed in the stroma and epithelium in lung cancer.</p><p id="Par73">Regulatory T-lymphocytes (Tregs) are a subset of CD4<sup>+</sup> T cells that contribute to an immunosuppressive TME by secreting interleukin 10 (IL-10) and transforming growth factor &#x003b2; (TGF&#x003b2;). TGF&#x003b2; promotes the transcription of Forkhead box P3 (FOXP3), driving the differentiation of na&#x000ef;ve CD4 T cells into Tregs [<xref ref-type="bibr" rid="CR22">22</xref>]. Elevated levels of tumour-infiltrating Tregs are associated with poorer overall survival in lung cancer [<xref ref-type="bibr" rid="CR23">23</xref>]. In contrast to conventional CD4<sup>+</sup> T cells that enhance immune responses, Tregs maintain immune homeostasis and self-tolerance by suppressing the activity of other immune cells, thereby preventing autoimmune reactions. The IL-10 and TGF&#x003b2; produced by Tregs inhibit the activation of effector T cells and other immune cells, promoting tumour immune evasion.</p><p id="Par74">CAFs are the predominant cell type in lung cancer. Unlike normal fibroblasts which are typically inactive and supports the extracellular matrix (ECM) during wound healing, CAF undergoes irreversible activation. Moreover, they also have increased migratory and proliferative abilities and secrete various molecules. CAFs play crucial roles in immune evasion, metastasis, invasion, angiogenesis, and drug resistance, thus enhancing the TME [<xref ref-type="bibr" rid="CR24">24</xref>]. Furthermore, CAFs are involved in stimulating inflammation which facilitates tumour growth. As CAFs can secrete cytokines and chemokines, these molecules recruit and activate immune cells, and their reciprocal interactions contribute to the TME. In lung cancer, CAFs produce an excess of tryptophan 2&#x02013;3-dioxygenase (TDO2) which inhibits dendritic cell differentiation [<xref ref-type="bibr" rid="CR25">25</xref>]. Recent studies have identified subtypes of CAFs, such as myofibroblastic CAFs (myCAFs), which are key in promoting tumour growth and therapy resistance. Targeting myCAFs or combining strategies with immunotherapy may enhance treatment outcomes [<xref ref-type="bibr" rid="CR26">26</xref>].</p><p id="Par75">Natural Killer (NK) cells are cytotoxic lymphocytes that kill cancer cells and exhibit strong antitumour effect in many cancers including lung cancer. These cells are predominantly found in the invasive margin surrounding tumour lesions and rarely contacts cancer cells directly. They provide strong protection during the early lung cancer stage, but this effect diminishes as cancer progresses. Defective NK cells in the TME are characterized by reduced toxicity, decreased responsiveness to stimuli and impaired survival [<xref ref-type="bibr" rid="CR27">27</xref>]. Additionally, defective NK cells and T cell exhaustion are observed in the TME of lung cancer [<xref ref-type="bibr" rid="CR6">6</xref>]. For example, NK cells may not be able to penetrate the tumour tissues, even with sufficient signalling by chemokines. This has been observed in NSCLC tissues, where NK cells were reported to exist within the stroma that contained active cytokine secretion, but NK cells failed to come into contact and kill tumour cells. The effects of NF-&#x003ba;B and STAT3 pathways on the lung TME and the cells within is illustrated in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref> and the roles of major immune and stromal cells in the lung cancer TME is tabulated in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> below.<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>The effects of NF-&#x003ba;B and STAT3 pathways on the lung TME and the cells within</p></caption><graphic xlink:href="12032_2025_2765_Fig2_HTML" id="MO3"/></fig><table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Roles of major immune and stromal cells in the lung cancer TME</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Cell Type</th><th align="left">Key Functions &#x00026; Effects</th><th align="left">Reference</th></tr></thead><tbody><tr><td align="left">TAMs (M1)</td><td align="left">&#x02022; Produce IL-12, IL-23 (antitumour, cytotoxic)</td><td align="left">[<xref ref-type="bibr" rid="CR18">18</xref>]</td></tr><tr><td align="left">TAMs (M2)</td><td align="left"><p>&#x02022; Promote stroma formation, angiogenesis, metastasis</p><p>&#x02022; Dominant in lung cancer TME</p></td><td align="left">[<xref ref-type="bibr" rid="CR18">18</xref>]</td></tr><tr><td align="left">MDSCs</td><td align="left"><p>&#x02022; Suppress T cells</p><p>&#x02022; Secrete VEGF (promotes angiogenesis)</p><p>&#x02022; Correlate with poor prognosis</p></td><td align="left">[<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]</td></tr><tr><td align="left">CD8&#x02009;+&#x02009;T Cells</td><td align="left"><p>&#x02022; Kill cancer cells</p><p>&#x02022; Dysfunctional in advanced lung cancer</p></td><td align="left">[<xref ref-type="bibr" rid="CR21">21</xref>]</td></tr><tr><td align="left">CD4&#x02009;+&#x02009;T Cells (Tregs)</td><td align="left"><p>&#x02022; Secrete IL-10, TGF&#x003b2; (immunosuppressive)</p><p>&#x02022; Linked to poorer survival</p><p>&#x02022; Inhibit effector T cells</p></td><td align="left">[<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]</td></tr><tr><td align="left">CAFs</td><td align="left"><p>&#x02022; Promote immune evasion, metastasis, angiogenesis</p><p>&#x02022; Secrete TDO2 (inhibits dendritic cells)</p></td><td align="left">[<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]</td></tr><tr><td align="left">NK Cells</td><td align="left"><p>&#x02022; Early antitumour activity</p><p>&#x02022; Defective in advanced stages (reduced cytotoxicity)</p></td><td align="left">[<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec6"><title>Effect of NF-&#x003ba;B and STAT3 pathways on cellular and molecular components within the lung TME</title><p id="Par76">The NF-&#x003ba;B pathway activates cytokine IL-6, which then interacts with its receptors to subsequently activate the STAT3 signalling pathway. In turn, STAT3 upregulates microRNA-135b (miR-135b), which further activates NF-&#x003ba;B pathway. This crosstalk establishes a positive-feedback loop between the NF-&#x003ba;B and STAT3 pathways, enhancing the progression of NSCLC [<xref ref-type="bibr" rid="CR28">28</xref>]. The overall impact of the NF-&#x003ba;B and STAT3 pathways on cells within the TME is summarized in the lower half of Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>.</p><p id="Par77">STAT3 is often activated in immune cells infiltrating tumours. In myeloid cells, aberrant STAT3 activation contributes to lung cancer progression by recruiting immunosuppressive cell including regulatory T cells (Tregs), MDSCs and alternatively activated macrophages (M2 macrophage) into the TME. STAT3 regulates M2 macrophages to facilitate tumour growth by promoting immune evasion, supressing immune responses, and enhancing angiogenesis [<xref ref-type="bibr" rid="CR22">22</xref>]. Tumour-derived gamma-aminobutyric acid (GABA), a neurotransmitter, inhibits M1 macrophage polarization via the JAK2/STAT3 pathways, thereby promoting cancer progression. Additionally, Jumonji Domain-Containing Protein 6 (JMJD6) expressed on the surface of macrophage induces dose-dependent STAT3 phosphorylation, leading to increased expression of the immunosuppressive cytokine IL-10 in TAM through the STAT3 pathway [<xref ref-type="bibr" rid="CR29">29</xref>].</p><p id="Par78">NF-&#x003ba;B transcription factors also activate TAMs in the tumour stroma to secrete inflammatory cytokines, which suppresses dendritic cells (DCs) maturation and inhibits the adaptive immune response necessary for tumour rejection. When NF-&#x003ba;B is activated by stimuli such as TLR ligands, IL-1&#x003b2;, and TNF-&#x003b1;, it can directly induce macrophage differentiation into M1 phenotype of TAMs, which generally exerts tumour-suppressive effects. However, under different conditions, this activation of NF-&#x003ba;B may also promote the expression of genes that facilitate M2 macrophage polarization, thereby contributing to tumour progression [<xref ref-type="bibr" rid="CR30">30</xref>]. NF-&#x003ba;B can also be activated by I&#x003ba;KB and has another role of preventing lipopolysaccharide LPS-induced apoptosis in macrophages. Therefore, macrophages deficient in I&#x003ba;KB, have higher sensitivity to LPS-induced apoptosis, and are essentially not effective [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p id="Par79">STAT3 also plays a crucial role in regulating MDSC, promoting their development and proliferation within tumours. It reduces the production of pro-apoptotic mediators, thereby facilitating apoptosis in cytotoxic T cells that are responsible for eliminating cancers cells. Persistent activation of STAT3 in MDSCs induces the production of immunosuppressive cytokines such as IL-10, TGF&#x003b2;, and NOX2, which support Treg formation and inhibit dendritic cell (DC) function. Additionally, M2 macrophage and MDSCs secrete cytokines like IL-6 and IL-11, which activate STAT3 and create a signalling loop that fosters a TME favourable for cancer cells.</p><p id="Par80">Research indicates that the expression of polypeptide N-acetyl-galactosaminyltransferase 3 (GALNT3) is diminished in lung cancer tissues compared to normal lung tissues. Low levels of GALNT3 are associated with poorer prognosis in cancer patients. GALNT3 restricts the recruitment of polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) by inhibiting the self-renewal of lung cancer cells, which leads to the downregulation of CXCL1. This downregulation is mediated by reduced &#x003b2;-catenin levels, decreased nuclear localization of NF-&#x003ba;B, and diminished c-MET-induced phosphorylation of protein kinase B (AKT) [<xref ref-type="bibr" rid="CR19">19</xref>]. Therefore, the increased nuclear localization of NF-&#x003ba;B will increase CXCL1 expression and decrease levels of GALNT3 allowing the recruitment of PMN-MDSCs within the lung TME.</p><p id="Par81">Tumour cell-intrinsic STAT3 induces expression of MHC class I, which hinders the cytotoxic activity of NK cells [<xref ref-type="bibr" rid="CR31">31</xref>]. Besides that, STAT3 also exerts a negative regulatory effect on NK cells activity; its overexpression in NK cells diminishes their cytotoxic function. On the other hand, research directly investigating the role of NF-&#x003ba;B in NK cells within the context of cancer remains limited. One study suggests that within the TME, hypoxia-induced HIF-1&#x003b1; expression inhibits IL-18-mediated NF-&#x003ba;B activation in tumour-infiltrating NK cells. This inhibition resulted in compromised NK cell function and allowed for unchecked tumour growth [<xref ref-type="bibr" rid="CR32">32</xref>].</p><p id="Par82">In lung cancer, T cells frequently exhibit an exhausted phenotype, characterized by decreased secretion of inflammatory cytokines and reduced cytotoxic activity. STAT3 can attenuate the immune response of T cells by impairing their recruitment, proliferation, and survival. Additionally, STAT3 modulates the expression of immune checkpoint proteins such as PD1 and CTLA4 on T cells, thereby influencing immune tolerance [<xref ref-type="bibr" rid="CR22">22</xref>]. Conversely, NF-&#x003ba;B is essential for the maturation and functionality of CD8<sup>+</sup> T cells. In particular, the activation of RelA, which occurs downstream of T cell receptor (TCR) engagement, is crucial for the optimal expression of Eomesodermin (Eomes), a transcription factor required for the development and function of T cells. Moreover, the production of interferon-gamma (IFN-&#x003b3;) by CD8<sup>+</sup> T cells rely on NF-&#x003ba;B<bold>,</bold> as evidenced by reduced IFN-&#x003b3; levels in mice with conditional deletion of RelA in T cells. These findings underscore the significant role of NF-&#x003ba;B in regulating T cell activation, survival, and function, particularly in the context of cancer [<xref ref-type="bibr" rid="CR32">32</xref>].</p><p id="Par83">STAT3 can enhance the production of Tregs by directly binding to the FOXP3 promoter or by interacting with the promoter of TGF&#x003b2; and IL-10 in Tregs. Furthermore, STAT3 signalling upregulates CTLA4 expression on Tregs through the IL-10 receptor, thereby augmenting their immunosuppressive ability. On the other hand, excessive activation of NF-&#x003ba;B pathway diminishes T cell function and promotes the activation of Tregs, contributing to immunosuppression. Numerous studies have shown that NF-&#x003ba;B proteins, particularly C-Rel, are vital not only for the transcription of FOXP3 but also for the development of Tregs in the thymus and the function of activated Treg cells (aTregs). The NF-&#x003ba;B pathway also plays a significant role in regulating CTLA4 expression, as well as in the development and maintenance of Treg cells, further contributing to immunosuppression within TME [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p id="Par84">CAFs are key mediators of immune suppression, extracellular matrix deposition and remodelling, creating a favourable TME that supports cancer progression. The JAK/STAT signalling pathway is constitutively activated in CAFs, and these cells secrete cytokines such as IL-6, IL-10, IL-11, and IL-22, ligands which further amplify the JAK/STAT signalling cascade. Through the IL-6/STAT3 signalling pathway, CAFs enhance the metastatic potential of lung cancer cells, promoting angiogenesis by elevating VEGF and bFGF levels, facilitating cancer invasion and migration. Persistent STAT3 activation in CAFs fosters pro-angiogenic, migratory, and invasive phenotype. Moreover, activation of the JAK/STAT3 signalling cascade can also induce mesenchymal stem cells to differentiate into CAFs within the TME [<xref ref-type="bibr" rid="CR22">22</xref>]. Besides the role of NF-KB pathway on cancer cells, it is also involved in immune cells such as CAFs and TAMs. It has crucial involvement in CAFs, contributing to their tumour-promoting effects [<xref ref-type="bibr" rid="CR33">33</xref>]. TLRs are immune cell surface receptors which have been linked to growth of lung cancer cells via anti-apoptotic signals and proliferation [<xref ref-type="bibr" rid="CR34">34</xref>]. Autophagy mediated HMGB1 is a protein that binds to the TLR4 cell surface receptor which can drive CAFs to affect the NF-&#x003ba;B pathway in lung cancer, contributing to its metastasis [<xref ref-type="bibr" rid="CR35">35</xref>].</p><p id="Par85">Vascular endothelial growth factor (VEGF) primarily signals through VEGF receptor 2 (VEGFR-2), leading to the activation of STAT3. This activation involves STAT3 dimerization, nuclear translocation, and DNA binding. Once bound to DNA, STAT3 regulates the transcription of genes essential for endothelial cells activation, vascular inflammation, and other related biological processes. A positive-feedback loop is established where VEGF-induced STAT3 activation can directly upregulate the VEGF promoter [<xref ref-type="bibr" rid="CR36">36</xref>]. Additionally, phosphorylation of JAK2 and subsequent activation of STAT3 can further enhance VEGF/VEGFR-2 signalling, resulting in increased blood vessel permeability. Besides that, NF-&#x003ba;B enhances angiogenesis by upregulating the production of CXCR4 and CXCL8 which are chemokine receptors that subsequently increases VEGFs [<xref ref-type="bibr" rid="CR12">12</xref>]. The NF-&#x003ba;B and STAT3 pathway interactions in lung cancer TME is tabulated in Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref> below.<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>NF-&#x003ba;B and STAT3 pathway interactions in lung cancer TME</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Pathway</th><th align="left">Target Cells</th><th align="left">Pro-Tumour Effects</th><th align="left">Key Mediators</th><th align="left">Reference</th></tr></thead><tbody><tr><td align="left" rowspan="4">NF-&#x003ba;B</td><td align="left">Macrophages</td><td align="left"><p>&#x02022; M1/M2 polarization balance</p><p>&#x02022; Anti-apoptosis (via I&#x003ba;KB)</p><p>&#x02022; DC suppression</p></td><td align="left">TLR ligands, IL-1&#x003b2;, TNF-&#x003b1;</td><td align="left">[<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]</td></tr><tr><td align="left">T cells</td><td align="left"><p>&#x02022; CD8&#x02009;+&#x02009;T cell maturation</p><p>&#x02022; IFN-&#x003b3; production</p><p>&#x02022; Treg development</p></td><td align="left">RelA, Eomes, FOXP3</td><td align="left">[<xref ref-type="bibr" rid="CR32">32</xref>]</td></tr><tr><td align="left">CAFs</td><td align="left"><p>&#x02022; ECM remodelling</p><p>&#x02022; Metastasis (via HMGB1/TLR4)</p></td><td align="left">CXCL8, CXCR4</td><td align="left">[<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]</td></tr><tr><td align="left">Angiogenesis</td><td align="left">&#x02022; VEGF upregulation</td><td align="left">CXCL1, &#x003b2;-catenin</td><td align="left">[<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]</td></tr><tr><td align="left" rowspan="5">STAT3</td><td align="left">Macrophages</td><td align="left"><p>&#x02022; M2 polarization</p><p>&#x02022; IL-10 production</p></td><td align="left">GABA, JMJD6</td><td align="left">[<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]</td></tr><tr><td align="left">MDSCs</td><td align="left"><p>&#x02022; Expansion</p><p>&#x02022; Immunosuppression (IL-10/TGF&#x003b2;)</p></td><td align="left">NOX2</td><td align="left">[<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]</td></tr><tr><td align="left">T cells</td><td align="left"><p>&#x02022; T cell exhaustion</p><p>&#x02022; PD1/CTLA4 upregulation</p><p>&#x02022; Treg differentiation</p></td><td align="left">FOXP3, IL-10</td><td align="left">[<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]</td></tr><tr><td align="left">CAFs</td><td align="left"><p>&#x02022; Pro-angiogenic phenotype</p><p>&#x02022; MSC differentiation</p></td><td align="left">VEGF, bFGF</td><td align="left">[<xref ref-type="bibr" rid="CR22">22</xref>]</td></tr><tr><td align="left">NK cells</td><td align="left"><p>&#x02022; Cytotoxicity inhibition</p><p>&#x02022; MHC I upregulation</p></td><td align="left">HIF-1&#x003b1;</td><td align="left">[<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec7"><title>Interaction between cells within the lung TME contributing to tumour development</title><p id="Par86">The interactions between TME components and cells influences tumour aggression and metastasis by enabling cancer cells to acquire an invasive phenotype and spread to distant sites through a metastatic complex [<xref ref-type="bibr" rid="CR37">37</xref>]. These interactions can also affect tumour growth, angiogenesis as well as immune response and evasion. For example, the interaction of MDSCs with various other cells results in tumour development. MDSCs facilitates the recruitment and formation of Tregs, suppressing the antitumour activity of T cells. Elevated levels of MDSCs with high expression of iNOS and L-arginase I, inhibits the formation of protective CD8<sup>+</sup> T cell via reduction of CD3&#x003b6; chain expression, consequently impairing their immune functionality. Moreover, MDSCs directly induce the expression of T cell exhaustion inhibitory receptors on CD8<sup>+</sup> T cells, including PD-1, TIGIT, LAG3, CTLA4, and TIM3. For instance, programmed cell death protein 1 (PD-1) interacts with its ligand PD-L1, leading to the inhibition of CD8<sup>+</sup> T cell proliferation, survival, and cytokine secretion. This interaction impairs immune function, promotes T cells exhaustion, and enhances resistance to immune checkpoint inhibitors (ICIs) thereby facilitating tumour progression [<xref ref-type="bibr" rid="CR21">21</xref>].</p><p id="Par87">Tregs promote angiogenesis by directly increasing levels of VEGF-A and/or IL-10 or by influencing other immune cells to secrete pro-angiogenic cytokines [<xref ref-type="bibr" rid="CR38">38</xref>]. Tregs-induced angiogenesis can also be facilitated through the VEGFA/VEGFR2 signalling pathway. Tregs can inhibit the functions of CD8<sup>+</sup> T cells and dendritic cells via membrane-bound TGF-&#x003b2;, thereby modulating the body&#x02019;s antitumour immune response. Moreover, Tregs can upregulate the TME by suppressing the secretion of IFN-&#x003b3; by CD8<sup>+</sup> T cells, in turn preventing inhibition of sterol regulatory element-binding protein 1 (SREBP1)-dependent fatty acid metabolism which is essential in immunosuppressive M2-(TAMs) survival [<xref ref-type="bibr" rid="CR39">39</xref>].</p><p id="Par88">In addition, CAFs enhances immune suppression by interacting with M2 macrophages and MDSCs. CAFs inhibits the proliferation of both CD4<sup>+</sup> and CD8<sup>+</sup> T cell and reduce the expansion of CD8<sup>+</sup> T cells within the stimulated CD3<sup>+</sup> T cells. They also upregulate PD1 protein expression on CD4<sup>+</sup> and CD8<sup>+</sup> T cell [<xref ref-type="bibr" rid="CR40">40</xref>]. Pro-inflammatory cytokines released by CAFs recruit macrophages, neutrophils, and lymphocytes to the tumour stroma. These recruited cells differentiate into TAMs and tumour-associated neutrophils (TANs) which subsequently produces key factors such as VEGF, HGF, MMPs and interleukins, which promotes endothelial growth [<xref ref-type="bibr" rid="CR41">41</xref>].</p></sec></sec><sec id="Sec8"><title>Therapeutic implications</title><sec id="Sec9"><title>STAT3</title><p id="Par89">STAT3 is an important target in the therapy of lung cancer as it plays various crucial roles in tumour development including tumour cell proliferation, tumour cell survival and evasion of pathogen from the immune system. It is primarily activated by two major pathways which are the mTOR and JAK pathways. The inhibition of both these pathways provides an effective strategy in overcoming the activation of the STAT3, which would directly inhibit the development and progression of lung cancer.</p><p id="Par90">In the case of the mTOR pathway, its inhibition has emerged as a promising therapeutic strategy by promoting apoptosis in cancer cells and overcoming resistance towards treatments. This is because mTOR can activate the STAT3 pathway and together, the mTOR/STAT3 pathway promotes the development of tumours [<xref ref-type="bibr" rid="CR42">42</xref>]. Hence, therapeutic strategies that focus on inhibiting the mTOR pathway, which subsequently inhibits the STAT3 activation, need to be implemented.</p><p id="Par91">There are several mTOR inhibitors being studied and developed to have enhanced selectivity and robust anti-cancer effects. Amongst these would be the dual-action pharmacological agents that can modulate two targets simultaneously, such as CC-115 which suppresses both mTORC1 and mTORC2 pathways along with the DNA-dependent protein kinase (DNA-PK), which inhibits cancer cell growth in vivo and in vitro [<xref ref-type="bibr" rid="CR43">43</xref>].</p><p id="Par92">Additionally, mTOR also regulates the programmed death ligand 1 (PD-L1) expression, which allows for cancer cells to evade or inhibit the immune system. Therefore, with the combination of mTOR inhibitors and ICIs such as PD-1/PD-L1 blockers, research shows that therapeutic efficacy is elevated, which has potential to overcome the development of resistance [<xref ref-type="bibr" rid="CR44">44</xref>]. For example, the mTOR inhibitor vistusertib combined with ICIs such as &#x003b1;PD-1, &#x003b1;CTLA-4 and &#x003b1;PD-L1, produced synergistic anti-cancer effects compared to when these agents were administered individually [<xref ref-type="bibr" rid="CR45">45</xref>].</p><p id="Par93">Moreover, researchers have proposed new immune checkpoint molecules, such as TIM-3, LAG-3 and TIGIT, to overcome resistance of the cancer cells to ICIs [<xref ref-type="bibr" rid="CR6">6</xref>]. These molecules play a role in the modulation of multiple aspects of the immune response, resulting in a versatile attack on the tumour. There is also an improvement in antitumour immunity when mTOR inhibitors are combined with these immune checkpoint molecules.</p><p id="Par94">Furthermore, transcription factors are responsible for the mediation of the mTOR signalling pathway, causing gene expression reprogramming, which ultimately promotes the growth of tumour as well as its survival. So, to inhibit the mTOR pathway to avoid activation of STAT3, the transcription factors must be targeted, and to do so, small molecule inhibitors must be deployed. For instance, studies have shown that PP242 can inhibit both the mTORC1/2 pathway [<xref ref-type="bibr" rid="CR46">46</xref>]. Thus, targeting the transcription factors involved may be an effective method to avoid the activation of STAT3 pathway.</p><p id="Par95">The JAK pathway also could activate STAT3. Hence, multiple measures can be taken to inhibit the JAK pathway by extension disrupts the STAT3 pathway, which plays a critical role in lung TME. These inhibitors work by targeting different JAK family members, as shown in Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>, thus interfering with THE STAT3 pathway which is a crucial signalling pathway that promote cancer cell survival and proliferation through gene expression.&#x000a0;For instance, Ruxolitinib, an inhibitor of JAK1 and JAK2, competitively inhibits the ATP-binding catalytic site on these kinases [<xref ref-type="bibr" rid="CR47">47</xref>]. A Phase Ib study combining ruxolitinib with afatinib, an EGFR inhibitor, in NSCLC patients demonstrated that this regiment was well-tolerated and displayed activity against the malignancy, with 23.3% showing partial responses and 80% having stable disease [<xref ref-type="bibr" rid="CR48">48</xref>]. However, despite these promising results, many trials with ruxolitinib have been underperforming, potentially due to its impact on immune cell function, which might counteract its anti-cancer effects.<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Apoptosis promoting properties of the inhibitors such as ruxolitinib, AZD4205 (Golidocitinib), fedratinib and filgotinib, supresses the activation of STAT3 by inhibiting the phosphorylation of tyrosine by JAK, whereas CC-115, DNA-PK, TIM-3, LAG-3, TIGIT PP242 and the combination of vistusertib with aPD-1, ACTLA-4 or aPD-L1 inhibits the activation of STAT3 by supressing the phosphorylation of serine by JAK. The inactivation of the STAT3 pathway inhibits its ability to drive tumour formation via gene expression, hence ultimately inhibiting the growth, survival, and proliferation of tumour cells</p></caption><graphic xlink:href="12032_2025_2765_Fig3_HTML" id="MO4"/></fig></p><p id="Par96">Moreover, AZD4205 (Golidocitinib), a selective JAK1 inhibitor, has also shown significant pre-clinical efficacy [<xref ref-type="bibr" rid="CR49">49</xref>]. In a pre-clinical NSCLC in vivo model, AZD4205 treatment inhibited both tumour growth and STAT3 activation [<xref ref-type="bibr" rid="CR50">50</xref>]. These effects were more pronounced when AZD4205 was used in combination with osimertinib, another EGFR inhibitor [<xref ref-type="bibr" rid="CR51">51</xref>]. This combination has progressed to Phase I/II clinical trials, highlighting its potential therapeutic value [<xref ref-type="bibr" rid="CR50">50</xref>]. On the other hand, Fedratinib targets JAK2 and has been found to be effective in NSCLC cells with elevated JAK2 expression [<xref ref-type="bibr" rid="CR52">52</xref>]. In combination with erlotinib, an EGFR tyrosine kinase inhibitor, fedratinib decreased STAT3 activation and increased apoptosis in erlotinib-resistant NSCLC cells, also inhibiting tumour growth in murine models [<xref ref-type="bibr" rid="CR53">53</xref>].</p><p id="Par97">Furthermore, Filgotinib, a selective JAK1 inhibitor, reduces levels of cytokines such as IL-6 and inhibits STAT3 activation in NSCLC cells [<xref ref-type="bibr" rid="CR54">54</xref>]. Filgotinib demonstrates similar efficacy in inhibiting JAK1-mediated IFN&#x003b1;, and IL-6 responses compared to other JAK inhibitors [<xref ref-type="bibr" rid="CR55">55</xref>]. In NCI-H889 lung cancer cells, derived from a metastatic site, Filgotinib effectively inhibited STAT3 activation, underscoring its potential in targeting the TME [<xref ref-type="bibr" rid="CR56">56</xref>]. In short, the mTOR and JAK pathways affects the activation of STAT3, which leads to tumour development and progression. Hence, necessary measures need to be taken in order to inhibit the activation of STAT3 at its roots.</p></sec><sec id="Sec10"><title>NFKB</title><p id="Par98">Inhibitors of the NF-&#x003ba;B pathway have significant therapeutic implications for lung tumours by disrupting key signalling mechanisms that contribute to tumour growth and survival. For instance, Siltuximab is an IL-6 inhibitor that fully eliminates IL-6 signal transduction in vivo and in vitro, effectively inhibiting lung cancer proliferation [<xref ref-type="bibr" rid="CR57">57</xref>]. In a phase I/II clinical trial evaluating its efficacy in solid tumours, including pancreatic cancer, siltuximab was well tolerated but showed no significant clinical activity, with adverse events such as abnormal liver function and fatigue occurring in more than 10% of patients [<xref ref-type="bibr" rid="CR58">58</xref>]. Despite promising in vitro and in vivo results, further research is needed to improve clinical outcomes for cancer patients [<xref ref-type="bibr" rid="CR59">59</xref>].</p><p id="Par99">Additionally, Bortezomib, a proteasome inhibitor, indirectly targets the NF-&#x003ba;B pathway by interfering with the degradation of key regulatory proteins [<xref ref-type="bibr" rid="CR60">60</xref>]. Adding bortezomib to standard chemotherapy regimens holds promise for enhancing treatment efficacy, especially in advanced stages of SCLC. In one study conducted both pre-clinical and clinical studies, bortezomib has shown significant therapeutic benefits in multiple myeloma (MM) [<xref ref-type="bibr" rid="CR56">56</xref>]. Bone marrow stromal cells (BMSCs) can upregulate IL-6 expression via NF-&#x003ba;B &#x02013;dependent mechanisms, suggesting that inhibiting NF-&#x003ba;B could reduce IL-6 levels and prevent the triggering of terminal differentiation. Research indicates that bortezomib can downregulate NF-&#x003ba;B target genes in both pre-clinical and clinical settings, highlighting its potential in cancer therapy [<xref ref-type="bibr" rid="CR61">61</xref>]. Moreover, bortezomib induces cell cycle arrest at G2/M phase transition in replicating cells in vitro, disrupting cell cycle progression and leading to apoptosis [<xref ref-type="bibr" rid="CR62">62</xref>]. This effect is partly due to the inhibition of the NF-&#x003ba;B pathway. Additionally, bortezomib reduces VEGF secretion within the bone marrow microenvironment, inhibiting the activation of caveolin-1, a protein crucial for motility of a cell and angiogenesis. This inhibition of VEGF-triggered tyrosine phosphorylation and subsequent angiogenetic processes has been validated through in vivo experimentation [<xref ref-type="bibr" rid="CR63">63</xref>]. Clinical trials have further supported the use of bortezomib in combination with pemetrexed, demonstrating that this combination is both tolerable and effective for patients with advanced solid tumours, including NSCLC [<xref ref-type="bibr" rid="CR64">64</xref>].</p><p id="Par100">Furthermore, Carfilzomib is an irreversible second-generation proteosome inhibitor that has shown promising results in cancer treatment [<xref ref-type="bibr" rid="CR65">65</xref>]. In multiple myeloma (MM) cells exposed to carfilzomib, both the extrinsic and intrinsic apoptotic pathways are activated, leading to significant increases in caspases-3,-7,-8, and &#x02013;9 [<xref ref-type="bibr" rid="CR61">61</xref>]. Caspase-3 and caspase-7 are critical effector caspases that exist as inactive zymogens and once activated by initiators, inactivate various structural and functional proteins, culminating in apoptosis [<xref ref-type="bibr" rid="CR66">66</xref>]. Caspase-8 initiates the death receptor pathway, whilst caspase-9 initiates the mitochondrial pathway [<xref ref-type="bibr" rid="CR66">66</xref>]. Both caspases are located upstream in their respective pathways and are essential for transmitting and amplifying apoptotic signals, thereby activating downstream effector genes that induce apoptosis [<xref ref-type="bibr" rid="CR66">66</xref>]. Compared to bortezomib, carfilzomib exhibits minimal off-target activity beyond the proteasome, enabling it to induce apoptosis in both bortezomib-naive and bortezomib pre-treated MM cells without increasing toxicity [<xref ref-type="bibr" rid="CR56">56</xref>]. This specificity, along with its higher affinity for the proteosome, contributes to carfilzomib&#x02019;s superior efficacy in xenograft models [<xref ref-type="bibr" rid="CR61">61</xref>]. These attributes suggest that carfilzomib may offer a potent antitumour response with fewer side effects compared to bortezomib, highlighting its potential as a more effective treatment option for patients with MM [<xref ref-type="bibr" rid="CR67">67</xref>].</p><p id="Par101">Besides that, Doxorubicin Hydrochloride works by inducing phosphorylation and degradation in I&#x003ba;B, leading to the inhibition of NF-&#x003ba;B in A549 human lung adenocarcinoma cell lines, as shown in Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref> [<xref ref-type="bibr" rid="CR49">49</xref>]. When combined with sulfasalazine, doxorubicin&#x02019;s cytotoxicity is enhanced, inhibiting TNF-&#x003b1; in NF-&#x003ba;B activation [<xref ref-type="bibr" rid="CR49">49</xref>]. On the other hand, Bevacizumab is a humanised monoclonal antibody against VEGF, used in combination with standard chemotherapeutics for treating stage IIIb and IV NSCLC [<xref ref-type="bibr" rid="CR68">68</xref>]. Bevacizumab decreases NF-&#x003ba;B levels, countering the increase induced by treatments like TBi, which helps in reducing tumour proliferation and improving patient outcomes [<xref ref-type="bibr" rid="CR69">69</xref>].<fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p>The NF-&#x003ba;B pathway in a macrophage is activated by TNF-&#x003b1;, which leads to tumour formation. To inhibit TNF- &#x003b1; binding, doxorubicin can be deployed. Secondly, carfilzomib induces caspase activation and Siltuximab which inhibits IL-6 are treatments that trailed to be administer to patients. Fourthly, Bortezomib targets both NF-&#x003ba;B via IL-6 and VEGF. Lastly, Bevacizumab is shown to decrease VEGF levels to counter tumour proliferation. The pathway also highlights the role of TAMs in the TME and the downstream effects of STAT3 activation, promoting tumour growth and immune evasion</p></caption><graphic xlink:href="12032_2025_2765_Fig4_HTML" id="MO5"/></fig></p></sec><sec id="Sec11"><title>Other relevant factors affecting TME</title><p id="Par102">There are several therapeutic implications of several other factors that also affect the TME, causing progression of cancer. For instance, the immunosuppressive cells MDSC which stimulates the growth of tumour by the suppression of CD4<sup>+</sup> and CD8<sup>+</sup> T cells, which are essential immune cells that have antitumour properties. CD8<sup>+</sup> recognises tumour cells sign their MHC class-I receptor and causes the tumour cells to lyse whereas CD4<sup>+</sup> can be differentiated into several T helper (Th) cells and Treg cells that secrete cytokines to protect the host from pathogens [<xref ref-type="bibr" rid="CR70">70</xref>]. Inhibition of such vital cells causes the proliferation and growth of tumour cells. Hence, to modulate the activity of MDSC, measures need to be taken to reduce its ability to suppress the T cells. For example, bacterial strains, such as <italic>Klebsiella pneumoniae</italic> and <italic>Pseudomonas aeruginosa</italic>, have been shown to produce necessary metabolites that are able to suppress the function of MDSC, thereby avoiding the CD4<sup>+</sup> and CD8<sup>+</sup> T cells suppression, which ultimately enhances the antitumour immunity [<xref ref-type="bibr" rid="CR71">71</xref>].</p><p id="Par103">Besides that, to enhance the function and activity of CD8<sup>+</sup> T cells, probiotics and prebiotics can be combined and used with pre-existing immunotherapies to improve the therapeutic outcomes. Example of probiotics includes <italic>lactobacillus rhamnosus</italic>, which stimulates dendritic cells through the Toll-like receptor 2 (TLR2) pathway hence activating the CD8<sup>+</sup> T cells, as well as <italic>Eubacterium hallii</italic>, which promotes the activation of CD8<sup>+</sup> T cells and allows them to easily infiltrate into the tumours [<xref ref-type="bibr" rid="CR72">72</xref>, <xref ref-type="bibr" rid="CR73">73</xref>]. On the other hand, prebiotics such as inulin triggers the T cells activation, which leads to an increase in the number of CD8<sup>+</sup> T cells produced [<xref ref-type="bibr" rid="CR74">74</xref>].</p><p id="Par104">Additionally, the Treg cell, which is the differentiated naive CD4<sup>+</sup> T cells, can inhibit the immune responses that are excessive or uncontrolled, leading to the suppression of immune cells such as T cells, B cells and natural killer (NK) cells [<xref ref-type="bibr" rid="CR75">75</xref>]. Therefore, the microbiome should be modulated to reduce the activity of Treg cells. Just like MDSC, Treg cells can be modulated using bile acid metabolite in bacteria from the Bacteroidetes species, isoallolithocholic acid (isoalloLCA), which has the potential to promote the differentiation of Treg cells [<xref ref-type="bibr" rid="CR76">76</xref>].</p><p id="Par105">Another factor that affects TME is the cells that detect and eradicate tumour cells in the preliminary stages of lung cancer by playing a vital role in the innate immune response system, which are the NK cells [<xref ref-type="bibr" rid="CR77">77</xref>]. To enhance the potency of NK cells against tumour cells, there is a strategy known as the chemical antigen receptor (CAR) technology. Originally, this technology was used to produce T cells but now it has been adapted to produce CAR-NK cells using the same domain used to produce CAR-T cells [<xref ref-type="bibr" rid="CR78">78</xref>].</p><p id="Par106">Furthermore, TAMs are macrophages that can polarise into pro-tumoural or antitumoural phenotypes depending on TME. Several bacterial products can polarise TAMs into the antitumoural phenotype, which allows them to lyse tumour cells [<xref ref-type="bibr" rid="CR79">79</xref>]. Therefore, more research needs to be conducted to detect which bacterial products affect the polarisation and to determine if the bacteria could be safely introduced to the body to increase the potency of TAMs.
</p><p id="Par107">Other than that, CAFs have the ability to promote tumours by stimulating growth and metastasis. Hence, CAFs have to be inhibited, and this is possible by using clodronate-containing liposomes (Clo-Lipo-DOTAP) to clear TAMs which significantly suppresses the development of tumour [<xref ref-type="bibr" rid="CR80">80</xref>]. On the other hand, VEGF plays a significant role in angiogenesis by providing blood supply to tumours and allowing them to grow. It does this by targeting the endothelial cells of blood vessels which triggers an intracellular signalling pathway that leads to the formation of new blood vessels. Therefore, to inhibit the VEGF signalling pathways that cause angiogenesis, there are several FDA approved drugs that can be used, such as Bevacizumab, which has potent inhibitory ability [<xref ref-type="bibr" rid="CR81">81</xref>].</p><p id="Par108">In short, studying and understanding the modulation of the TME and the relevant factors contributing to its balance, as listed in Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>, has the potential to offer new directions especially in improving the efficacy of current cancer treatments. Further research into the microbial interactions and their effects on immune cells holds immense potential significantly in the development of new therapies aiming to help patients suffering from lung cancer.<table-wrap id="Tab4"><label>Table&#x000a0;4</label><caption><p>Overview of Therapeutic Agents Targeting TME Pathways</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Target</th><th align="left">Therapeutic Approach</th><th align="left">Key Agents</th><th align="left">Mechanism/Outcome</th><th align="left">Reference</th></tr></thead><tbody><tr><td align="left" rowspan="2">STAT3</td><td align="left">mTOR pathway inhibition</td><td align="left">CC-115, PP242, Vistusertib&#x02009;+&#x02009;ICIs (&#x003b1;PD-1/&#x003b1;PD-L1/&#x003b1;CTLA-4)</td><td align="left">Blocks STAT3 activation; enhances apoptosis and combats ICI resistance</td><td align="left">[<xref ref-type="bibr" rid="CR42">42</xref>&#x02013;<xref ref-type="bibr" rid="CR46">46</xref>]</td></tr><tr><td align="left">JAK pathway inhibition</td><td align="left">Ruxolitinib (JAK1/2), AZD4205 (JAK1), Fedratinib (JAK2), Filgotinib (JAK1)</td><td align="left">Reduces STAT3 phosphorylation; inhibits tumour growth (synergy with EGFR inhibitors)</td><td align="left">[<xref ref-type="bibr" rid="CR47">47</xref>&#x02013;<xref ref-type="bibr" rid="CR56">56</xref>]</td></tr><tr><td align="left" rowspan="3">NF-&#x003ba;B</td><td align="left">IL-6 inhibition</td><td align="left">Siltuximab</td><td align="left">Suppresses IL-6 signalling; inhibits proliferation (limited clinical efficacy)</td><td align="left">[<xref ref-type="bibr" rid="CR57">57</xref>&#x02013;<xref ref-type="bibr" rid="CR59">59</xref>]</td></tr><tr><td align="left">Proteasome inhibition</td><td align="left">Bortezomib, Carfilzomib</td><td align="left">Induces apoptosis via caspase activation; reduces VEGF/IL-6 (superior efficacy with carfilzomib)</td><td align="left">[<xref ref-type="bibr" rid="CR60">60</xref>&#x02013;<xref ref-type="bibr" rid="CR67">67</xref>]</td></tr><tr><td align="left">I&#x003ba;B degradation/VEGF blockade</td><td align="left">Doxorubicin&#x02009;+&#x02009;Sulfasalazine, Bevacizumab</td><td align="left">Inhibits NF-&#x003ba;B activation; counters angiogenesis</td><td align="left">[<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR68">68</xref>, <xref ref-type="bibr" rid="CR69">69</xref>]</td></tr><tr><td align="left" rowspan="7">Other TME Factors</td><td align="left">MDSC modulation</td><td align="left">Bacterial metabolites (Klebsiella/Pseudomonas)</td><td align="left">Suppresses MDSC function; restores CD4&#x02009;+&#x02009;/CD8&#x02009;+&#x02009;T cell activity</td><td align="left">[<xref ref-type="bibr" rid="CR70">70</xref>, <xref ref-type="bibr" rid="CR71">71</xref>]</td></tr><tr><td align="left">CD8&#x02009;+&#x02009;T cell enhancement</td><td align="left">Probiotics (Lactobacillus rhamnosus), Prebiotics (Inulin)</td><td align="left">Activates dendritic cells (TLR2) and boosts T cell infiltration</td><td align="left">[<xref ref-type="bibr" rid="CR72">72</xref>&#x02013;<xref ref-type="bibr" rid="CR74">74</xref>]</td></tr><tr><td align="left">Treg modulation</td><td align="left">Bacteroidetes-derived isoalloLCA</td><td align="left">Promotes Treg differentiation; balances immune response</td><td align="left">[<xref ref-type="bibr" rid="CR75">75</xref>, <xref ref-type="bibr" rid="CR76">76</xref>]</td></tr><tr><td align="left">NK cell enhancement</td><td align="left">CAR-NK cell therapy</td><td align="left">Improves tumour cell targeting via engineered receptors</td><td align="left">[<xref ref-type="bibr" rid="CR77">77</xref>, <xref ref-type="bibr" rid="CR78">78</xref>]</td></tr><tr><td align="left">TAM reprogramming</td><td align="left">Bacterial products</td><td align="left">Polarizes TAMs to antitumoural phenotype</td><td align="left">[<xref ref-type="bibr" rid="CR79">79</xref>]</td></tr><tr><td align="left">CAF inhibition</td><td align="left">Clo-Lipo-DOTAP</td><td align="left">Clears TAMs; suppresses tumour growth</td><td align="left">[<xref ref-type="bibr" rid="CR80">80</xref>]</td></tr><tr><td align="left">Angiogenesis inhibition</td><td align="left">Bevacizumab</td><td align="left">Blocks VEGF signalling; reduces blood vessel formation</td><td align="left">(<xref ref-type="bibr" rid="CR81">81</xref>)</td></tr></tbody></table></table-wrap></p></sec></sec><sec id="Sec12"><title>Conclusion</title><p id="Par109">In conclusion, the growth and progression of lung cancer are significantly influenced by the lung TME. The interaction and effects of the complex networks of cellular and non-cellular components, signalling molecules and extracellular matrix components enables cancer cells to proliferate, metastasize and evade the immune system. Therefore, it is crucial to target the components involved in the lung TME in cancer therapy due to their ability of creating a milieu that is favourable for tumour maturation and development.</p><p id="Par110">The pro-tumourigenic status of the TME is mainly dependent on two key signalling pathways, namely the NF-&#x003ba;B and STAT3 pathways. The activation of these two pathways leads to the upregulation and downregulation of the various cellular and non-cellular components in the TME, ultimately resulting in immune evasion, inhibition of apoptosis, angiogenesis, tumour cell proliferation, survival, and inflammation. Therefore, inhibiting the activation of these pathways represents a promising therapeutic strategy. Pre-clinical and clinical research have demonstrated the potential of targeting these pathways with inhibitors, such as mTOR and JAK inhibitors for the STAT3 pathway along with a few other inhibitors such as the IL-6 and VEGF inhibitors for the NF-&#x003ba;B pathway. These therapeutic strategies can help to improve patient outcomes and perhaps overcome resistance to current treatments.</p><p id="Par111">Overall, understanding the effects of the functions and interactions of the various cellular and non-cellular components in the TME such as regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), tumour-associated macrophages (TAMs), CAF, natural killer cells (NK), T cells and VEGF, offers additional insights into developing tailored therapeutic interventions. The interplay between these immune cells and the major pathways involved (NF-&#x003ba;B and STAT3) suggests that disrupting the TME and suppressing cancer progression may require a multimodal approach that involves immunomodulatory drugs as well as pathway inhibitors. For this reason, future research should focus on improving therapeutic efficacy and addressing resistance in lung cancer treatment.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>AKT</term><def><p id="Par3">Protein kinase B</p></def></def-item><def-item><term>CAFs</term><def><p id="Par4">Cancer-associated fibroblasts</p></def></def-item><def-item><term>CD4<sup>+</sup></term><def><p id="Par5">Cluster of differentiation 4 positive</p></def></def-item><def-item><term>CD8<sup>+</sup></term><def><p id="Par6">Cluster of differentiation 8 positive</p></def></def-item><def-item><term>CTLA4</term><def><p id="Par7">Cytotoxic T-lymphocyte associated protein 4</p></def></def-item><def-item><term>CXCR4</term><def><p id="Par8">C-X-C motif chemokine receptor 4</p></def></def-item><def-item><term>CXCL8</term><def><p id="Par9">C-X-C motif chemokine ligand 8</p></def></def-item><def-item><term>DC</term><def><p id="Par10">Dendritic Cells</p></def></def-item><def-item><term>ECM</term><def><p id="Par11">Extracellular matrix</p></def></def-item><def-item><term>FOXP3</term><def><p id="Par12">Forkhead box P3</p></def></def-item><def-item><term>GABA</term><def><p id="Par13">Gamma-A minobutyric acid</p></def></def-item><def-item><term>GALNT3</term><def><p id="Par14">Polypeptide N-acetyl-galactosaminyl transferase 3</p></def></def-item><def-item><term>HGF</term><def><p id="Par15">Hepatocyte growth factor</p></def></def-item><def-item><term>HIF</term><def><p id="Par16">Hypoxia-inducible factor</p></def></def-item><def-item><term>HIF-1&#x003b1;</term><def><p id="Par17">Hypoxia-inducible factor-1 &#x003b1;</p></def></def-item><def-item><term>HMGB1</term><def><p id="Par18">High mobility group box 1</p></def></def-item><def-item><term>IAPs</term><def><p id="Par19">Inhibitors of apoptosis</p></def></def-item><def-item><term>ICIs</term><def><p id="Par20">Immune checkpoint inhibitors</p></def></def-item><def-item><term>IFN-&#x003b3;</term><def><p id="Par21">Interferon-gamma</p></def></def-item><def-item><term>IKK</term><def><p id="Par22">Inhibitory kappa B kinase</p></def></def-item><def-item><term>IL</term><def><p id="Par23">Interleukin</p></def></def-item><def-item><term>iNOS</term><def><p id="Par24">Inducible nitric oxide synthase</p></def></def-item><def-item><term>JAK</term><def><p id="Par25">Janus kinase</p></def></def-item><def-item><term>JMJD6</term><def><p id="Par26">Jumonji domain-containing protein 6</p></def></def-item><def-item><term>LAG3</term><def><p id="Par27">Lymphocyte-activation gene 3</p></def></def-item><def-item><term>LPS</term><def><p id="Par28">Lipopolysaccharide</p></def></def-item><def-item><term>MDSCs</term><def><p id="Par29">Myeloid-derived suppressor cells</p></def></def-item><def-item><term>miR-135b</term><def><p id="Par30">MicroRNA-135b</p></def></def-item><def-item><term>MMPs</term><def><p id="Par31">Matrix metalloproteinases</p></def></def-item><def-item><term>mTORC1</term><def><p id="Par32">Mechanistic target of rapamycin complex 1</p></def></def-item><def-item><term>myCAFs</term><def><p id="Par33">Myofibroblastic CAFs</p></def></def-item><def-item><term>NF-&#x003ba;B</term><def><p id="Par34">Nuclear factor kappa B</p></def></def-item><def-item><term>NK</term><def><p id="Par35">Natural killer</p></def></def-item><def-item><term>PD1</term><def><p id="Par36">Programmed cell death protein 1</p></def></def-item><def-item><term>PD-L1</term><def><p id="Par37">Programmed death ligand 1</p></def></def-item><def-item><term>PMN-MDSCs</term><def><p id="Par38">Polymorphonuclear myeloid-derived suppressor cells</p></def></def-item><def-item><term>NOX2</term><def><p id="Par39">NADPH oxidase 2</p></def></def-item><def-item><term>NSCLC</term><def><p id="Par40">Non-small cell lung cancer</p></def></def-item><def-item><term>SCLC</term><def><p id="Par41">Small cell lung cancer</p></def></def-item><def-item><term>SREBP1</term><def><p id="Par42">Sterol regulatory element-binding protein 1</p></def></def-item><def-item><term>SRGN</term><def><p id="Par43">Serglycin</p></def></def-item><def-item><term>STAT3</term><def><p id="Par44">Signal transducer and activator of transcription 3</p></def></def-item><def-item><term>TAMs</term><def><p id="Par45">Tumour-associated macrophages</p></def></def-item><def-item><term>TANs</term><def><p id="Par46">Tumour-associated neutrophils</p></def></def-item><def-item><term>TCR</term><def><p id="Par47">T cell receptor</p></def></def-item><def-item><term>TDO2</term><def><p id="Par48">Tryptophan 2&#x02013;3-dioxygenase</p></def></def-item><def-item><term>TGF&#x003b2;</term><def><p id="Par49">Transforming growth factor &#x003b2;</p></def></def-item><def-item><term>TIGIT</term><def><p id="Par50">T cell immunoreceptor with Ig and ITIM domains</p></def></def-item><def-item><term>TIM3</term><def><p id="Par51">T cell immunoglobulin and mucin-domain containing-3</p></def></def-item><def-item><term>TNF-&#x003b1;</term><def><p id="Par52">Tumour necrosis factor alpha</p></def></def-item><def-item><term>Th2</term><def><p id="Par53">T helper 2</p></def></def-item><def-item><term>TLR</term><def><p id="Par54">Toll-like receptor</p></def></def-item><def-item><term>TME</term><def><p id="Par55">Tumour microenvironment</p></def></def-item><def-item><term>Tregs</term><def><p id="Par56">Regulatory T cells</p></def></def-item><def-item><term>VEGF</term><def><p id="Par57">Vascular endothelial growth factor</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author contributions</title><p>The authors confirm their contribution to the paper as follows: study conception and design: G. B. Y., and R. S.Y. W. Data collection: D. T. E., J. K. A. S. S., and L. Y. Q. Draft manuscript preparation: L. H. X., L. W. T., S. V. A. S, and T. E. W. All authors approved the final version of the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open Access funding enabled and organized by CAUL and its Member Institutions. The research was supported financially by the Sunway University Early Career Research Grant Scheme (GRTIN-ECR-SBMDC-05&#x02013;2024), Sunway University Research Accelerator Grant Scheme (GRTIN-RAG-SBMDC-10&#x02013;2024), (GRTIN-RAG(02)-DPSY-08&#x02013;2024) and (GRTIN-RAG-SBMDC-05&#x02013;2025).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>No datasets were generated or analyzed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par112">The authors declare no competing interests.</p></notes><notes id="FPar2"><title>Ethical approval</title><p id="Par113">Not applicable</p></notes><notes id="FPar3"><title>Consent to participate</title><p id="Par114">Not applicable</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="book"><person-group person-group-type="author"><name><surname>Faraz</surname><given-names>S</given-names></name><name><surname>Sarosh</surname><given-names>V</given-names></name></person-group><source>Abdul HS</source><year>2024</year><publisher-loc>Lung Cancer</publisher-loc><publisher-name>StatPearls Publishing</publisher-name><fpage>2024</fpage></element-citation><mixed-citation id="mc-CR1" publication-type="book">Faraz S, Sarosh V. Abdul HS. Lung Cancer: StatPearls Publishing; 2024. p. 2024.</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">World HO. Lung cancer 2023 Available from: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/news-room/fact-sheets/detail/lung-cancer">https://www.who.int/news-room/fact-sheets/detail/lung-cancer</ext-link>.</mixed-citation></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Yuan</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name></person-group><article-title>Identification and validation of tumor microenvironment-related signature for predicting prognosis and immunotherapy response in patients with lung adenocarcinoma</article-title><source>Sci Rep</source><year>2023</year><volume>13</volume><issue>1</issue><fpage>13568</fpage><pub-id pub-id-type="doi">10.1038/s41598-023-40980-2</pub-id><pub-id pub-id-type="pmid">37604869</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Li C, Yuan Y, Jiang X, Wang Q. Identification and validation of tumor microenvironment-related signature for predicting prognosis and immunotherapy response in patients with lung adenocarcinoma. Sci Rep. 2023;13(1):13568.<pub-id pub-id-type="pmid">37604869</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Nasser</surname><given-names>KA</given-names></name><name><surname>Geoffrey</surname><given-names>JM</given-names></name><name><surname>Dingcheng</surname><given-names>G</given-names></name><name><surname>Jeffrey</surname><given-names>LP</given-names></name><name><surname>Ashish</surname><given-names>S</given-names></name><name><surname>Brendon</surname><given-names>S</given-names></name><etal/></person-group><article-title>The lung microenvironment: an important regulator of tumour growth and metastasis</article-title><source>Nat Rev Cancer</source><year>2019</year><volume>19</volume><fpage>9</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1038/s41568-018-0081-9</pub-id><pub-id pub-id-type="pmid">30532012</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Nasser KA, Geoffrey JM, Dingcheng G, Jeffrey LP, Ashish S, Brendon S, et al. The lung microenvironment: an important regulator of tumour growth and metastasis. Nat Rev Cancer. 2019;19:9&#x02013;31.<pub-id pub-id-type="pmid">30532012</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Stephanie</surname><given-names>T</given-names></name><name><surname>Rajwanth</surname><given-names>V</given-names></name><name><surname>Wil</surname><given-names>L-C</given-names></name><name><surname>Sacha</surname><given-names>G</given-names></name><name><surname>Francesca</surname><given-names>P</given-names></name><name><surname>Pei</surname><given-names>W</given-names></name><etal/></person-group><article-title>Prognostic value of immune cells in the tumor microenvironment of early-stage lung cancer: a meta-analysis</article-title><source>Oncotarget</source><year>2019</year><volume>10</volume><issue>67</issue><fpage>7142</fpage><lpage>7155</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.27392</pub-id><pub-id pub-id-type="pmid">31903172</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Stephanie T, Rajwanth V, Wil L-C, Sacha G, Francesca P, Pei W, et al. Prognostic value of immune cells in the tumor microenvironment of early-stage lung cancer: a meta-analysis. Oncotarget. 2019;10(67):7142&#x02013;55.<pub-id pub-id-type="pmid">31903172</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Genova</surname><given-names>C</given-names></name><name><surname>Dellepiane</surname><given-names>C</given-names></name><name><surname>Carrega</surname><given-names>P</given-names></name><name><surname>Sommariva</surname><given-names>S</given-names></name><name><surname>Ferlazzo</surname><given-names>G</given-names></name><name><surname>Pronzato</surname><given-names>P</given-names></name><etal/></person-group><article-title>Therapeutic implications of tumor microenvironment in lung cancer: focus on immune checkpoint blockade</article-title><source>Front Immunol</source><year>2021</year><volume>12</volume><fpage>799455</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2021.799455</pub-id><pub-id pub-id-type="pmid">35069581</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Genova C, Dellepiane C, Carrega P, Sommariva S, Ferlazzo G, Pronzato P, et al. Therapeutic implications of tumor microenvironment in lung cancer: focus on immune checkpoint blockade. Front Immunol. 2021;12: 799455.<pub-id pub-id-type="pmid">35069581</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Nishida</surname><given-names>A</given-names></name><name><surname>Andoh</surname><given-names>A</given-names></name></person-group><article-title>The role of inflammation in cancer: mechanisms of tumor initiation, progression, and metastasis</article-title><source>Cells</source><year>2005</year><volume>14</volume><issue>7</issue><fpage>488</fpage><pub-id pub-id-type="doi">10.3390/cells14070488</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Nishida A, Andoh A. The role of inflammation in cancer: mechanisms of tumor initiation, progression, and metastasis. Cells. 2005;14(7):488.</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>X</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Su</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Su</surname><given-names>X</given-names></name><name><surname>Ding</surname><given-names>X</given-names></name><etal/></person-group><article-title>Lactate-induced activation of tumor-associated fibroblasts and IL-8-mediated macrophage recruitment promote lung cancer progression</article-title><source>Redox Biol</source><year>2024</year><volume>74</volume><fpage>103209</fpage><pub-id pub-id-type="doi">10.1016/j.redox.2024.103209</pub-id><pub-id pub-id-type="pmid">38861833</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Gu X, Zhu Y, Su J, Wang S, Su X, Ding X, et al. Lactate-induced activation of tumor-associated fibroblasts and IL-8-mediated macrophage recruitment promote lung cancer progression. Redox Biol. 2024;74: 103209.<pub-id pub-id-type="pmid">38861833</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Kuczynski</surname><given-names>EA</given-names></name><name><surname>Reynolds</surname><given-names>AR</given-names></name></person-group><article-title>Vessel co-option and resistance to anti-angiogenic therapy</article-title><source>Angiogenesis</source><year>2020</year><volume>23</volume><issue>1</issue><fpage>55</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1007/s10456-019-09698-6</pub-id><pub-id pub-id-type="pmid">31865479</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Kuczynski EA, Reynolds AR. Vessel co-option and resistance to anti-angiogenic therapy. Angiogenesis. 2020;23(1):55&#x02013;74.<pub-id pub-id-type="pmid">31865479</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>JY</given-names></name><name><surname>Hsu</surname><given-names>HS</given-names></name><name><surname>Tyan</surname><given-names>SW</given-names></name><name><surname>Li</surname><given-names>FY</given-names></name><name><surname>Shew</surname><given-names>JY</given-names></name><name><surname>Lee</surname><given-names>WH</given-names></name><etal/></person-group><article-title>Serglycin in tumor microenvironment promotes non-small cell lung cancer aggressiveness in a CD44-dependent manner</article-title><source>Oncogene</source><year>2017</year><volume>36</volume><issue>17</issue><fpage>2457</fpage><lpage>2471</lpage><pub-id pub-id-type="doi">10.1038/onc.2016.404</pub-id><pub-id pub-id-type="pmid">27819672</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Guo JY, Hsu HS, Tyan SW, Li FY, Shew JY, Lee WH, et al. Serglycin in tumor microenvironment promotes non-small cell lung cancer aggressiveness in a CD44-dependent manner. Oncogene. 2017;36(17):2457&#x02013;71.<pub-id pub-id-type="pmid">27819672</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>Z</given-names></name><name><surname>Xue</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Song</surname><given-names>Y</given-names></name><name><surname>Qi</surname><given-names>Y</given-names></name></person-group><article-title>The role of tumor inflammatory microenvironment in lung cancer</article-title><source>Front Pharmacol</source><year>2021</year><volume>12</volume><fpage>688625</fpage><pub-id pub-id-type="doi">10.3389/fphar.2021.688625</pub-id><pub-id pub-id-type="pmid">34079469</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Tan Z, Xue H, Sun Y, Zhang C, Song Y, Qi Y. The role of tumor inflammatory microenvironment in lung cancer. Front Pharmacol. 2021;12: 688625.<pub-id pub-id-type="pmid">34079469</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Ebrahimi</surname><given-names>N</given-names></name><name><surname>Abdulwahid</surname><given-names>ARR</given-names></name><name><surname>Mansouri</surname><given-names>A</given-names></name><name><surname>Karimi</surname><given-names>N</given-names></name><name><surname>Bostani</surname><given-names>RJ</given-names></name><name><surname>Beiranvand</surname><given-names>S</given-names></name><etal/></person-group><article-title>Targeting the NF-kappaB pathway as a potential regulator of immune checkpoints in cancer immunotherapy</article-title><source>Cell Mol Life Sci</source><year>2024</year><volume>81</volume><issue>1</issue><fpage>106</fpage><pub-id pub-id-type="doi">10.1007/s00018-023-05098-8</pub-id><pub-id pub-id-type="pmid">38418707</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Ebrahimi N, Abdulwahid ARR, Mansouri A, Karimi N, Bostani RJ, Beiranvand S, et al. Targeting the NF-kappaB pathway as a potential regulator of immune checkpoints in cancer immunotherapy. Cell Mol Life Sci. 2024;81(1):106.<pub-id pub-id-type="pmid">38418707</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Betzler</surname><given-names>AC</given-names></name><name><surname>Theodoraki</surname><given-names>MN</given-names></name><name><surname>Schuler</surname><given-names>PJ</given-names></name><name><surname>Doscher</surname><given-names>J</given-names></name><name><surname>Laban</surname><given-names>S</given-names></name><name><surname>Hoffmann</surname><given-names>TK</given-names></name><etal/></person-group><article-title>NF-kappaB and its role in checkpoint control</article-title><source>Int J Mol Sci.</source><year>2020</year><volume>21</volume><issue>11</issue><fpage>3949</fpage><pub-id pub-id-type="doi">10.3390/ijms21113949</pub-id><pub-id pub-id-type="pmid">32486375</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Betzler AC, Theodoraki MN, Schuler PJ, Doscher J, Laban S, Hoffmann TK, et al. NF-kappaB and its role in checkpoint control. Int J Mol Sci. 2020;21(11):3949.<pub-id pub-id-type="pmid">32486375</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Ludden</surname><given-names>CM</given-names></name><name><surname>Cullen</surname><given-names>AJ</given-names></name><name><surname>Tew</surname><given-names>KD</given-names></name><name><surname>Branco de Barros</surname><given-names>AL</given-names></name><name><surname>Townsend</surname><given-names>DM</given-names></name></person-group><article-title>Nuclear factor kappa B expression in non-small cell lung cancer</article-title><source>Biomed Pharmacother</source><year>2023</year><pub-id pub-id-type="doi">10.1016/j.biopha.2023.115459</pub-id><pub-id pub-id-type="pmid">38157643</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Zhang L, Ludden CM, Cullen AJ, Tew KD, Branco de Barros AL, Townsend DM. Nuclear factor kappa B expression in non-small cell lung cancer. Biomed Pharmacother. 2023. 10.1016/j.biopha.2023.115459.<pub-id pub-id-type="pmid">38157643</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Morelli</surname><given-names>AP</given-names></name><name><surname>Tortelli</surname><given-names>TC</given-names><suffix>Jr</suffix></name><name><surname>Mancini</surname><given-names>MCS</given-names></name><name><surname>Pavan</surname><given-names>ICB</given-names></name><name><surname>Silva</surname><given-names>LGS</given-names></name><name><surname>Severino</surname><given-names>MB</given-names></name><etal/></person-group><article-title>STAT3 contributes to cisplatin resistance, modulating EMT markers, and the mTOR signaling in lung adenocarcinoma</article-title><source>Neoplasia</source><year>2021</year><volume>23</volume><issue>10</issue><fpage>1048</fpage><lpage>1058</lpage><pub-id pub-id-type="doi">10.1016/j.neo.2021.08.003</pub-id><pub-id pub-id-type="pmid">34543857</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Morelli AP, Tortelli TC Jr, Mancini MCS, Pavan ICB, Silva LGS, Severino MB, et al. STAT3 contributes to cisplatin resistance, modulating EMT markers, and the mTOR signaling in lung adenocarcinoma. Neoplasia. 2021;23(10):1048&#x02013;58.<pub-id pub-id-type="pmid">34543857</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Ellie</surname><given-names>R</given-names></name><name><surname>James</surname><given-names>TM</given-names></name><name><surname>Andrew</surname><given-names>RT</given-names></name></person-group><article-title>Oncogenic signalling through mechanistic target of rapamycin (mTOR): a driver of metabolic transformation and cancer progression</article-title><source>Cancers (Basel)</source><year>2017</year><volume>10</volume><issue>1</issue><fpage>5</fpage></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Ellie R, James TM, Andrew RT. Oncogenic signalling through mechanistic target of rapamycin (mTOR): a driver of metabolic transformation and cancer progression. Cancers (Basel). 2017;10(1):5.</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Chang</surname><given-names>M</given-names></name><name><surname>Lin</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name></person-group><article-title>Updates on altered signaling pathways in tumor drug resistance</article-title><source>Visual Cancer Med</source><year>2024</year><pub-id pub-id-type="doi">10.1051/vcm/2024007</pub-id><pub-id pub-id-type="pmid">39526457</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Li X, Huang X, Chang M, Lin R, Zhang J, Lu Y. Updates on altered signaling pathways in tumor drug resistance. Visual Cancer Med. 2024. 10.1051/vcm/2024007.<pub-id pub-id-type="pmid">39526457</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhuchen</surname><given-names>Y</given-names></name><name><surname>Juntao</surname><given-names>Z</given-names></name><name><surname>Fei</surname><given-names>X</given-names></name></person-group><article-title>Tumor-associated macrophages affect the treatment of lung cancer</article-title><source>Heliyon</source><year>2024</year><volume>10</volume><issue>7</issue><fpage>e29332</fpage><pub-id pub-id-type="doi">10.1016/j.heliyon.2024.e29332</pub-id><pub-id pub-id-type="pmid">38623256</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Zhuchen Y, Juntao Z, Fei X. Tumor-associated macrophages affect the treatment of lung cancer. Heliyon. 2024;10(7): e29332.<pub-id pub-id-type="pmid">38623256</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Rao</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Lei</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><etal/></person-group><article-title>Myeloid-derived suppressor cells in cancer: therapeutic targets to overcome tumor immune evasion</article-title><source>Exp Hematol Oncol</source><year>2024</year><volume>13</volume><issue>1</issue><fpage>39</fpage><pub-id pub-id-type="doi">10.1186/s40164-024-00505-7</pub-id><pub-id pub-id-type="pmid">38609997</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Lu J, Luo Y, Rao D, Wang T, Lei Z, Chen X, et al. Myeloid-derived suppressor cells in cancer: therapeutic targets to overcome tumor immune evasion. Exp Hematol Oncol. 2024;13(1):39.<pub-id pub-id-type="pmid">38609997</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Ngaha</surname><given-names>TYS</given-names></name><name><surname>Zhilenkova</surname><given-names>AV</given-names></name><name><surname>Essogmo</surname><given-names>FE</given-names></name><name><surname>Uchendu</surname><given-names>IK</given-names></name><name><surname>Abah</surname><given-names>MO</given-names></name><name><surname>Fossa</surname><given-names>LT</given-names></name><etal/></person-group><article-title>Angiogenesis in lung cancer: understanding the roles of growth factors</article-title><source>Cancers</source><year>2023</year><pub-id pub-id-type="doi">10.3390/cancers15184648</pub-id><pub-id pub-id-type="pmid">37760616</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Ngaha TYS, Zhilenkova AV, Essogmo FE, Uchendu IK, Abah MO, Fossa LT, et al. Angiogenesis in lung cancer: understanding the roles of growth factors. Cancers. 2023. 10.3390/cancers15184648.<pub-id pub-id-type="pmid">37760616</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>Z-N</given-names></name><name><surname>Zhang</surname><given-names>C-Y</given-names></name><name><surname>Zhao</surname><given-names>Y-W</given-names></name><name><surname>He</surname><given-names>S-L</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Shi</surname><given-names>B-L</given-names></name><etal/></person-group><article-title>Regulation of T cells by myeloid-derived suppressor cells: emerging immunosuppressor in lung cancer</article-title><source>Disc Oncol</source><year>2023</year><pub-id pub-id-type="doi">10.1007/s12672-023-00793-1</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">He Z-N, Zhang C-Y, Zhao Y-W, He S-L, Li Y, Shi B-L, et al. Regulation of T cells by myeloid-derived suppressor cells: emerging immunosuppressor in lung cancer. Disc Oncol. 2023. 10.1007/s12672-023-00793-1.</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Parakh</surname><given-names>S</given-names></name><name><surname>Ernst</surname><given-names>M</given-names></name><name><surname>Poh</surname><given-names>AR</given-names></name></person-group><article-title>Multicellular effects of STAT3 in non-small cell lung cancer: mechanistic insights and therapeutic opportunities</article-title><source>Cancers (Basel)</source><year>2021</year><pub-id pub-id-type="doi">10.3390/cancers13246228</pub-id><pub-id pub-id-type="pmid">34944848</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Parakh S, Ernst M, Poh AR. Multicellular effects of STAT3 in non-small cell lung cancer: mechanistic insights and therapeutic opportunities. Cancers (Basel). 2021. 10.3390/cancers13246228.<pub-id pub-id-type="pmid">34944848</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Principe</surname><given-names>DR</given-names></name><name><surname>Chiec</surname><given-names>L</given-names></name><name><surname>Mohindra</surname><given-names>NA</given-names></name><name><surname>Munshi</surname><given-names>HG</given-names></name></person-group><article-title>Regulatory T-cells as an emerging barrier to immune checkpoint inhibition in lung cancer</article-title><source>Front Oncol</source><year>2021</year><volume>11</volume><fpage>684098</fpage><pub-id pub-id-type="doi">10.3389/fonc.2021.684098</pub-id><pub-id pub-id-type="pmid">34141625</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Principe DR, Chiec L, Mohindra NA, Munshi HG. Regulatory T-cells as an emerging barrier to immune checkpoint inhibition in lung cancer. Front Oncol. 2021;11: 684098.<pub-id pub-id-type="pmid">34141625</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Mathieson</surname><given-names>L</given-names></name><name><surname>Koppensteiner</surname><given-names>L</given-names></name><name><surname>Dorward</surname><given-names>DA</given-names></name><name><surname>O'Connor</surname><given-names>RA</given-names></name><name><surname>Akram</surname><given-names>AR</given-names></name></person-group><article-title>Cancer-associated fibroblasts expressing fibroblast activation protein and podoplanin in non-small cell lung cancer predict poor clinical outcome</article-title><source>Br J Cancer</source><year>2024</year><volume>130</volume><issue>11</issue><fpage>1758</fpage><lpage>1769</lpage><pub-id pub-id-type="doi">10.1038/s41416-024-02671-1</pub-id><pub-id pub-id-type="pmid">38582812</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Mathieson L, Koppensteiner L, Dorward DA, O&#x02019;Connor RA, Akram AR. Cancer-associated fibroblasts expressing fibroblast activation protein and podoplanin in non-small cell lung cancer predict poor clinical outcome. Br J Cancer. 2024;130(11):1758&#x02013;69.<pub-id pub-id-type="pmid">38582812</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Monteran</surname><given-names>L</given-names></name><name><surname>Erez</surname><given-names>N</given-names></name></person-group><article-title>The dark side of fibroblasts: cancer-associated fibroblasts as mediators of immunosuppression in the tumor microenvironment</article-title><source>Front Immunol</source><year>2019</year><volume>10</volume><fpage>1835</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.01835</pub-id><pub-id pub-id-type="pmid">31428105</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Monteran L, Erez N. The dark side of fibroblasts: cancer-associated fibroblasts as mediators of immunosuppression in the tumor microenvironment. Front Immunol. 2019;10:1835.<pub-id pub-id-type="pmid">31428105</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name></person-group><article-title>Targeting myofibroblastic cancer-associated fibroblasts (myCAFs): a promising strategy for overcoming tumor progression and immunotherapy resistance</article-title><source>Visual Cancer Med</source><year>2025</year><pub-id pub-id-type="doi">10.1051/vcm/2025005</pub-id><pub-id pub-id-type="pmid">40259788</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Wang D, Chen Z. Targeting myofibroblastic cancer-associated fibroblasts (myCAFs): a promising strategy for overcoming tumor progression and immunotherapy resistance. Visual Cancer Med. 2025. 10.1051/vcm/2025005.<pub-id pub-id-type="pmid">40259788</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Cong</surname><given-names>J</given-names></name><name><surname>Wei</surname><given-names>H</given-names></name></person-group><article-title>Natural killer cells in the lungs</article-title><source>Front Immunol</source><year>2019</year><volume>10</volume><fpage>1416</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.01416</pub-id><pub-id pub-id-type="pmid">31293580</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Cong J, Wei H. Natural killer cells in the lungs. Front Immunol. 2019;10:1416.<pub-id pub-id-type="pmid">31293580</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Mi</surname><given-names>Z</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Zheng</surname><given-names>B</given-names></name><etal/></person-group><article-title>STAT3/miR-135b/NF-kappaB axis confers aggressiveness and unfavorable prognosis in non-small-cell lung cancer</article-title><source>Cell Death Dis</source><year>2021</year><volume>12</volume><issue>5</issue><fpage>493</fpage><pub-id pub-id-type="doi">10.1038/s41419-021-03773-x</pub-id><pub-id pub-id-type="pmid">33990540</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Zhao J, Wang X, Mi Z, Jiang X, Sun L, Zheng B, et al. STAT3/miR-135b/NF-kappaB axis confers aggressiveness and unfavorable prognosis in non-small-cell lung cancer. Cell Death Dis. 2021;12(5):493.<pub-id pub-id-type="pmid">33990540</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Qian</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Ruan</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Cai</surname><given-names>C</given-names></name><etal/></person-group><article-title>The role of tumor-associated macrophages in lung cancer: From mechanism to small molecule therapy</article-title><source>Biomed Pharmacother</source><year>2024</year><pub-id pub-id-type="doi">10.1016/j.biopha.2023.116014</pub-id><pub-id pub-id-type="pmid">39689515</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Zhou Y, Qian M, Li J, Ruan L, Wang Y, Cai C, et al. The role of tumor-associated macrophages in lung cancer: From mechanism to small molecule therapy. Biomed Pharmacother. 2024. 10.1016/j.biopha.2023.116014.<pub-id pub-id-type="pmid">39689515</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Cornice</surname><given-names>J</given-names></name><name><surname>Verzella</surname><given-names>D</given-names></name><name><surname>Arboretto</surname><given-names>P</given-names></name><name><surname>Vecchiotti</surname><given-names>D</given-names></name><name><surname>Capece</surname><given-names>D</given-names></name><name><surname>Zazzeroni</surname><given-names>F</given-names></name><etal/></person-group><article-title>NF-kappaB: governing macrophages in cancer</article-title><source>Genes (Basel)</source><year>2024</year><pub-id pub-id-type="doi">10.3390/genes15020197</pub-id><pub-id pub-id-type="pmid">38397187</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Cornice J, Verzella D, Arboretto P, Vecchiotti D, Capece D, Zazzeroni F, et al. NF-kappaB: governing macrophages in cancer. Genes (Basel). 2024. 10.3390/genes15020197.<pub-id pub-id-type="pmid">38397187</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Mohrherr</surname><given-names>J</given-names></name><name><surname>Uras</surname><given-names>IZ</given-names></name><name><surname>Moll</surname><given-names>HP</given-names></name><name><surname>Casanova</surname><given-names>E</given-names></name></person-group><article-title>STAT3: versatile functions in non-small cell lung cancer</article-title><source>Cancers (Basel)</source><year>2020</year><pub-id pub-id-type="doi">10.3390/cancers12051107</pub-id><pub-id pub-id-type="pmid">32365499</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Mohrherr J, Uras IZ, Moll HP, Casanova E. STAT3: versatile functions in non-small cell lung cancer. Cancers (Basel). 2020. 10.3390/cancers12051107.<pub-id pub-id-type="pmid">32365499</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Lalle</surname><given-names>G</given-names></name><name><surname>Twardowski</surname><given-names>J</given-names></name><name><surname>Grinberg-Bleyer</surname><given-names>Y</given-names></name></person-group><article-title>NF-&#x003ba;B in cancer immunity: friend or foe?</article-title><source>Cells</source><year>2021</year><pub-id pub-id-type="doi">10.3390/cells10020355</pub-id><pub-id pub-id-type="pmid">33572260</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Lalle G, Twardowski J, Grinberg-Bleyer Y. NF-&#x003ba;B in cancer immunity: friend or foe? Cells. 2021. 10.3390/cells10020355.<pub-id pub-id-type="pmid">33572260</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>Q</given-names></name><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Ye</surname><given-names>X</given-names></name><name><surname>Shen</surname><given-names>X</given-names></name><name><surname>Lin</surname><given-names>M</given-names></name><etal/></person-group><article-title>NF-kappaB in biology and targeted therapy: new insights and translational implications</article-title><source>Signal Transduct Target Ther</source><year>2024</year><volume>9</volume><issue>1</issue><fpage>53</fpage><pub-id pub-id-type="doi">10.1038/s41392-024-01757-9</pub-id><pub-id pub-id-type="pmid">38433280</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Guo Q, Jin Y, Chen X, Ye X, Shen X, Lin M, et al. NF-kappaB in biology and targeted therapy: new insights and translational implications. Signal Transduct Target Ther. 2024;9(1):53.<pub-id pub-id-type="pmid">38433280</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Xie</surname><given-names>B</given-names></name><name><surname>Ye</surname><given-names>P</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>Z</given-names></name></person-group><article-title>Roles of toll-like receptors: from inflammation to lung cancer progression</article-title><source>Biomed Rep</source><year>2018</year><volume>8</volume><issue>2</issue><fpage>126</fpage><lpage>132</lpage><pub-id pub-id-type="pmid">29435270</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Gu J, Liu Y, Xie B, Ye P, Huang J, Lu Z. Roles of toll-like receptors: from inflammation to lung cancer progression. Biomed Rep. 2018;8(2):126&#x02013;32.<pub-id pub-id-type="pmid">29435270</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>Y</given-names></name><name><surname>Cao</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Zheng</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><etal/></person-group><article-title>Autophagic secretion of HMGB1 from cancer-associated fibroblasts promotes metastatic potential of non-small cell lung cancer cells via NFkappaB signaling</article-title><source>Cell Death Dis</source><year>2021</year><volume>12</volume><issue>10</issue><fpage>858</fpage><pub-id pub-id-type="doi">10.1038/s41419-021-04150-4</pub-id><pub-id pub-id-type="pmid">34552063</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Ren Y, Cao L, Wang L, Zheng S, Zhang Q, Guo X, et al. Autophagic secretion of HMGB1 from cancer-associated fibroblasts promotes metastatic potential of non-small cell lung cancer cells via NFkappaB signaling. Cell Death Dis. 2021;12(10):858.<pub-id pub-id-type="pmid">34552063</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="other">Wang L, Astone M, Alam SK, Zhu Z, Pei W, Frank DA, et al. 2020 Suppressing STAT3 activity protects the endothelial barrier from VEGF-mediated vascular permeability. bioRxiv.</mixed-citation></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Shao</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>FXC</given-names></name><name><surname>Mu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Role of tumor microenvironment in cancer progression and therapeutic strategy</article-title><source>Cancer Med</source><year>2023</year><volume>12</volume><issue>10</issue><fpage>11149</fpage><lpage>11165</lpage><pub-id pub-id-type="doi">10.1002/cam4.5698</pub-id><pub-id pub-id-type="pmid">36807772</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Wang Q, Shao X, Zhang Y, Zhu M, Wang FXC, Mu J, et al. Role of tumor microenvironment in cancer progression and therapeutic strategy. Cancer Med. 2023;12(10):11149&#x02013;65.<pub-id pub-id-type="pmid">36807772</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Lu&#x0017e;nik</surname><given-names>Z</given-names></name><name><surname>Anchouche</surname><given-names>S</given-names></name><name><surname>Dana</surname><given-names>R</given-names></name><name><surname>Yin</surname><given-names>J</given-names></name></person-group><article-title>Regulatory T cells in angiogenesis</article-title><source>J Immunol</source><year>2020</year><volume>205</volume><issue>10</issue><fpage>2557</fpage><lpage>2565</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.2000574</pub-id><pub-id pub-id-type="pmid">33168598</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Lu&#x0017e;nik Z, Anchouche S, Dana R, Yin J. Regulatory T cells in angiogenesis. J Immunol. 2020;205(10):2557&#x02013;65.<pub-id pub-id-type="pmid">33168598</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Jiang</surname><given-names>P</given-names></name><name><surname>Wei</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name></person-group><article-title>Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects</article-title><source>Mol Cancer</source><year>2020</year><volume>19</volume><issue>1</issue><fpage>116</fpage><pub-id pub-id-type="doi">10.1186/s12943-020-01234-1</pub-id><pub-id pub-id-type="pmid">32680511</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Li C, Jiang P, Wei S, Xu X, Wang J. Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects. Mol Cancer. 2020;19(1):116.<pub-id pub-id-type="pmid">32680511</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Hwang</surname><given-names>M</given-names></name><name><surname>Jang</surname><given-names>S</given-names></name><name><surname>Um</surname><given-names>SW</given-names></name></person-group><article-title>Immune regulatory function of cancer- associated fibroblasts in non-small cell lung cancer</article-title><source>Tuberc Respir Dis (Seoul)</source><year>2023</year><volume>86</volume><issue>4</issue><fpage>304</fpage><lpage>318</lpage><pub-id pub-id-type="doi">10.4046/trd.2022.0129</pub-id><pub-id pub-id-type="pmid">37345462</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Lee H, Hwang M, Jang S, Um SW. Immune regulatory function of cancer- associated fibroblasts in non-small cell lung cancer. Tuberc Respir Dis (Seoul). 2023;86(4):304&#x02013;18.<pub-id pub-id-type="pmid">37345462</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Joshi</surname><given-names>RS</given-names></name><name><surname>Kanugula</surname><given-names>SS</given-names></name><name><surname>Sudhir</surname><given-names>S</given-names></name><name><surname>Pereira</surname><given-names>MP</given-names></name><name><surname>Jain</surname><given-names>S</given-names></name><name><surname>Aghi</surname><given-names>MK</given-names></name></person-group><article-title>The role of cancer-associated fibroblasts in tumor progression</article-title><source>Cancers (Basel)</source><year>2021</year><pub-id pub-id-type="doi">10.3390/cancers13061399</pub-id><pub-id pub-id-type="pmid">34944922</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Joshi RS, Kanugula SS, Sudhir S, Pereira MP, Jain S, Aghi MK. The role of cancer-associated fibroblasts in tumor progression. Cancers (Basel). 2021. 10.3390/cancers13061399.<pub-id pub-id-type="pmid">34944922</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Vella</surname><given-names>A</given-names></name><name><surname>D&#x02019;Aversa</surname><given-names>E</given-names></name><name><surname>Api</surname><given-names>M</given-names></name><name><surname>Breveglieri</surname><given-names>G</given-names></name><name><surname>Allegri</surname><given-names>M</given-names></name><name><surname>Giacomazzi</surname><given-names>A</given-names></name><etal/></person-group><article-title>mTOR and STAT3 pathway hyper-activation is associated with elevated interleukin-6 levels in patients with shwachman-diamond syndrome: further evidence of lymphoid lineage impairment</article-title><source>Cancers</source><year>2020</year><pub-id pub-id-type="doi">10.3390/cancers12030597</pub-id><pub-id pub-id-type="pmid">32796774</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Vella A, D&#x02019;Aversa E, Api M, Breveglieri G, Allegri M, Giacomazzi A, et al. mTOR and STAT3 pathway hyper-activation is associated with elevated interleukin-6 levels in patients with shwachman-diamond syndrome: further evidence of lymphoid lineage impairment. Cancers. 2020. 10.3390/cancers12030597.<pub-id pub-id-type="pmid">32796774</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Gargalionis</surname><given-names>AN</given-names></name><name><surname>Papavassiliou</surname><given-names>KA</given-names></name><name><surname>Papavassiliou</surname><given-names>AG</given-names></name></person-group><article-title>Implication of mTOR signaling in NSCLC: mechanisms and therapeutic perspectives</article-title><source>Cells</source><year>2023</year><pub-id pub-id-type="doi">10.3390/cells12152014</pub-id><pub-id pub-id-type="pmid">37566093</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Gargalionis AN, Papavassiliou KA, Papavassiliou AG. Implication of mTOR signaling in NSCLC: mechanisms and therapeutic perspectives. Cells. 2023. 10.3390/cells12152014.<pub-id pub-id-type="pmid">37566093</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>S-Y</given-names></name></person-group><article-title>Searching for the real function of mTOR signaling in the regulation of PD-L1 expression</article-title><source>Transl Oncol</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.tranon.2020.100847</pub-id><pub-id pub-id-type="pmid">33395750</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Sun S-Y. Searching for the real function of mTOR signaling in the regulation of PD-L1 expression. Transl Oncol. 2020. 10.1016/j.tranon.2020.100847.<pub-id pub-id-type="pmid">33395750</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Langdon</surname><given-names>S</given-names></name><name><surname>Hughes</surname><given-names>A</given-names></name><name><surname>Taylor</surname><given-names>MA</given-names></name><name><surname>Kuczynski</surname><given-names>EA</given-names></name><name><surname>Mele</surname><given-names>DA</given-names></name><name><surname>Delpuech</surname><given-names>O</given-names></name><etal/></person-group><article-title>Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity</article-title><source>OncoImmunology</source><year>2018</year><pub-id pub-id-type="doi">10.1080/2162402X.2018.1458810</pub-id><pub-id pub-id-type="pmid">30221055</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Langdon S, Hughes A, Taylor MA, Kuczynski EA, Mele DA, Delpuech O, et al. Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity. OncoImmunology. 2018. 10.1080/2162402X.2018.1458810.<pub-id pub-id-type="pmid">30221055</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Rashid</surname><given-names>MM</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Jung</surname><given-names>BH</given-names></name></person-group><article-title>Evaluation of the antitumor effects of PP242 in a colon cancer xenograft mouse model using comprehensive metabolomics and lipidomics</article-title><source>Sci Rep</source><year>2020</year><volume>10</volume><issue>1</issue><fpage>17523</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-73721-w</pub-id><pub-id pub-id-type="pmid">33067464</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Rashid MM, Lee H, Jung BH. Evaluation of the antitumor effects of PP242 in a colon cancer xenograft mouse model using comprehensive metabolomics and lipidomics. Sci Rep. 2020;10(1):17523.<pub-id pub-id-type="pmid">33067464</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="book"><person-group person-group-type="author"><name><surname>Mawiyah</surname><given-names>H</given-names></name><name><surname>Ghufran</surname><given-names>A</given-names></name></person-group><source>Ruxolitinib</source><year>2023</year><publisher-loc>Treasure Island (FL)</publisher-loc><publisher-name>StatPearls Publishing LLC</publisher-name></element-citation><mixed-citation id="mc-CR47" publication-type="book">Mawiyah H, Ghufran A. Ruxolitinib. Treasure Island (FL): StatPearls Publishing LLC; 2023.</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>SP</given-names></name><name><surname>Min</surname><given-names>HH</given-names></name><name><surname>You</surname><given-names>JC</given-names></name><name><surname>Hye</surname><given-names>RK</given-names></name><name><surname>Byoung</surname><given-names>CC</given-names></name></person-group><article-title>A phase Ib study of the combination of afatinib and ruxolitinib in EGFR mutant NSCLC with progression on EGFR-TKIs</article-title><source>Lung Cancer</source><year>2019</year><volume>134</volume><fpage>46</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/j.lungcan.2019.05.030</pub-id><pub-id pub-id-type="pmid">31319994</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Ji SP, Min HH, You JC, Hye RK, Byoung CC. A phase Ib study of the combination of afatinib and ruxolitinib in EGFR mutant NSCLC with progression on EGFR-TKIs. Lung Cancer. 2019;134:46&#x02013;51.<pub-id pub-id-type="pmid">31319994</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>C</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Zhuang</surname><given-names>J</given-names></name></person-group><article-title>NF-kappaB inhibitors gifted by nature: the anticancer promise of polyphenol compounds</article-title><source>Biomed Pharmacother</source><year>2022</year><volume>156</volume><fpage>113951</fpage><pub-id pub-id-type="doi">10.1016/j.biopha.2022.113951</pub-id><pub-id pub-id-type="pmid">36411636</pub-id>
</element-citation><mixed-citation id="mc-CR49" publication-type="journal">Guan C, Zhou X, Li H, Ma X, Zhuang J. NF-kappaB inhibitors gifted by nature: the anticancer promise of polyphenol compounds. Biomed Pharmacother. 2022;156: 113951.<pub-id pub-id-type="pmid">36411636</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Zoya</surname><given-names>Q</given-names></name><name><surname>Daniel</surname><given-names>EJ</given-names></name><name><surname>Jennifer</surname><given-names>RG</given-names></name></person-group><article-title>Targeting the JAK/STAT pathway in solid tumors</article-title><source>J Cancer Meta Treat</source><year>2020</year><pub-id pub-id-type="doi">10.20517/2394-4722.2020.58</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Zoya Q, Daniel EJ, Jennifer RG. Targeting the JAK/STAT pathway in solid tumors. J Cancer Meta Treat. 2020. 10.20517/2394-4722.2020.58.</mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Han</surname><given-names>L</given-names></name><name><surname>Gong</surname><given-names>Y</given-names></name><name><surname>Xie</surname><given-names>C</given-names></name></person-group><article-title>Mechanisms and management of 3rd-generation EGFR-TKI resistance in advanced non-small cell lung cancer (Review)</article-title><source>Int J Oncol</source><year>2021</year><pub-id pub-id-type="doi">10.20517/2394-4722.2020.58</pub-id><pub-id pub-id-type="pmid">34779489</pub-id>
</element-citation><mixed-citation id="mc-CR51" publication-type="journal">He J, Huang Z, Han L, Gong Y, Xie C. Mechanisms and management of 3rd-generation EGFR-TKI resistance in advanced non-small cell lung cancer (Review). Int J Oncol. 2021. 10.20517/2394-4722.2020.58.<pub-id pub-id-type="pmid">34779489</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name><surname>Talpaz</surname><given-names>M</given-names></name><name><surname>Kiladjian</surname><given-names>J-J</given-names></name></person-group><article-title>Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis</article-title><source>Leukemia</source><year>2020</year><volume>35</volume><issue>1</issue><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1038/s41375-020-0954-2</pub-id><pub-id pub-id-type="pmid">32647323</pub-id>
</element-citation><mixed-citation id="mc-CR52" publication-type="journal">Talpaz M, Kiladjian J-J. Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis. Leukemia. 2020;35(1):1&#x02013;17.<pub-id pub-id-type="pmid">32647323</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name><surname>Mehrdad</surname><given-names>H</given-names></name><name><surname>Sahar</surname><given-names>A</given-names></name><name><surname>Mohsen</surname><given-names>R</given-names></name><name><surname>Nafisesadat</surname><given-names>A</given-names></name><name><surname>Kasra Talebi</surname><given-names>A</given-names></name><name><surname>Motahhar</surname><given-names>M</given-names></name><etal/></person-group><article-title>STAT3 as a newly emerging target in colorectal cancer therapy: tumorigenesis, therapy response, and pharmacological/nanoplatform strategies</article-title><source>Environ Res</source><year>2023</year><volume>233</volume><fpage>116458</fpage><pub-id pub-id-type="doi">10.1016/j.envres.2023.116458</pub-id><pub-id pub-id-type="pmid">37348629</pub-id>
</element-citation><mixed-citation id="mc-CR53" publication-type="journal">Mehrdad H, Sahar A, Mohsen R, Nafisesadat A, Kasra Talebi A, Motahhar M, et al. STAT3 as a newly emerging target in colorectal cancer therapy: tumorigenesis, therapy response, and pharmacological/nanoplatform strategies. Environ Res. 2023;233: 116458.<pub-id pub-id-type="pmid">37348629</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name><surname>Shimizu</surname><given-names>T</given-names></name><name><surname>Kawashiri</surname><given-names>SY</given-names></name><name><surname>Morimoto</surname><given-names>S</given-names></name><name><surname>Kawazoe</surname><given-names>Y</given-names></name><name><surname>Kuroda</surname><given-names>S</given-names></name><name><surname>Kawasaki</surname><given-names>R</given-names></name><etal/></person-group><article-title>Efficacy and safety of selective JAK 1 inhibitor filgotinib in active rheumatoid arthritis patients with inadequate response to methotrexate: comparative study with filgotinib and tocilizumab examined by clinical index as well as musculoskeletal ultrasound assessment (TRANSFORM study): study protocol for a randomized, open-label, parallel-group, multicenter, and non-inferiority clinical trial</article-title><source>Trials</source><year>2023</year><volume>24</volume><issue>1</issue><fpage>161</fpage><pub-id pub-id-type="doi">10.1186/s13063-023-07176-5</pub-id><pub-id pub-id-type="pmid">36869356</pub-id>
</element-citation><mixed-citation id="mc-CR54" publication-type="journal">Shimizu T, Kawashiri SY, Morimoto S, Kawazoe Y, Kuroda S, Kawasaki R, et al. Efficacy and safety of selective JAK 1 inhibitor filgotinib in active rheumatoid arthritis patients with inadequate response to methotrexate: comparative study with filgotinib and tocilizumab examined by clinical index as well as musculoskeletal ultrasound assessment (TRANSFORM study): study protocol for a randomized, open-label, parallel-group, multicenter, and non-inferiority clinical trial. Trials. 2023;24(1):161.<pub-id pub-id-type="pmid">36869356</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name><surname>Traves</surname><given-names>PG</given-names></name><name><surname>Murray</surname><given-names>B</given-names></name><name><surname>Campigotto</surname><given-names>F</given-names></name><name><surname>Galien</surname><given-names>R</given-names></name><name><surname>Meng</surname><given-names>A</given-names></name><name><surname>Di Paolo</surname><given-names>JA</given-names></name></person-group><article-title>JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib</article-title><source>Ann Rheum Dis</source><year>2021</year><volume>80</volume><issue>7</issue><fpage>865</fpage><lpage>875</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2020-219012</pub-id><pub-id pub-id-type="pmid">33741556</pub-id>
</element-citation><mixed-citation id="mc-CR55" publication-type="journal">Traves PG, Murray B, Campigotto F, Galien R, Meng A, Di Paolo JA. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib. Ann Rheum Dis. 2021;80(7):865&#x02013;75.<pub-id pub-id-type="pmid">33741556</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen-Hua</surname><given-names>C</given-names></name><name><surname>Peyton</surname><given-names>GG</given-names></name><name><surname>Zo&#x000eb;</surname><given-names>NR</given-names></name><name><surname>Jennifer</surname><given-names>JB</given-names></name><name><surname>Dian</surname><given-names>Y</given-names></name><name><surname>Rosanna</surname><given-names>KM</given-names></name><etal/></person-group><article-title>Molecular definition of a metastatic lung cancer state reveals a targetable CD109&#x02013;Janus kinase&#x02013;Stat axis</article-title><source>Nat Med</source><year>2017</year><volume>23</volume><fpage>291</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1038/nm.4285</pub-id><pub-id pub-id-type="pmid">28191885</pub-id>
</element-citation><mixed-citation id="mc-CR56" publication-type="journal">Chen-Hua C, Peyton GG, Zo&#x000eb; NR, Jennifer JB, Dian Y, Rosanna KM, et al. Molecular definition of a metastatic lung cancer state reveals a targetable CD109&#x02013;Janus kinase&#x02013;Stat axis. Nat Med. 2017;23:291&#x02013;300.<pub-id pub-id-type="pmid">28191885</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>L</given-names></name><name><surname>Smith</surname><given-names>MA</given-names></name><name><surname>Doshi</surname><given-names>P</given-names></name><name><surname>Sasser</surname><given-names>K</given-names></name><name><surname>Fulp</surname><given-names>W</given-names></name><name><surname>Altiok</surname><given-names>S</given-names></name><etal/></person-group><article-title>Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer</article-title><source>J Thorac Oncol</source><year>2014</year><volume>9</volume><issue>7</issue><fpage>974</fpage><lpage>982</lpage><pub-id pub-id-type="doi">10.1097/JTO.0000000000000193</pub-id><pub-id pub-id-type="pmid">24922005</pub-id>
</element-citation><mixed-citation id="mc-CR57" publication-type="journal">Song L, Smith MA, Doshi P, Sasser K, Fulp W, Altiok S, et al. Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer. J Thorac Oncol. 2014;9(7):974&#x02013;82.<pub-id pub-id-type="pmid">24922005</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Jiang</surname><given-names>W</given-names></name><name><surname>Dong</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Zhu</surname><given-names>W</given-names></name><name><surname>Zhou</surname><given-names>W</given-names></name></person-group><article-title>STAT3 inhibitors: a novel insight for anticancer therapy of pancreatic cancer</article-title><source>Biomolecules</source><year>2022</year><pub-id pub-id-type="doi">10.3390/biom12101450</pub-id><pub-id pub-id-type="pmid">36671475</pub-id>
</element-citation><mixed-citation id="mc-CR58" publication-type="journal">Li X, Jiang W, Dong S, Li W, Zhu W, Zhou W. STAT3 inhibitors: a novel insight for anticancer therapy of pancreatic cancer. Biomolecules. 2022. 10.3390/biom12101450.<pub-id pub-id-type="pmid">36671475</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name><surname>van Rhee</surname><given-names>F</given-names></name><name><surname>Rosenthal</surname><given-names>A</given-names></name><name><surname>Kanhai</surname><given-names>K</given-names></name><name><surname>Martin</surname><given-names>R</given-names></name><name><surname>Nishimura</surname><given-names>K</given-names></name><name><surname>Hoering</surname><given-names>A</given-names></name><etal/></person-group><article-title>Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease</article-title><source>Blood Adv</source><year>2022</year><volume>6</volume><issue>16</issue><fpage>4773</fpage><lpage>4781</lpage><pub-id pub-id-type="doi">10.1182/bloodadvances.2022007112</pub-id><pub-id pub-id-type="pmid">35793409</pub-id>
</element-citation><mixed-citation id="mc-CR59" publication-type="journal">van Rhee F, Rosenthal A, Kanhai K, Martin R, Nishimura K, Hoering A, et al. Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease. Blood Adv. 2022;6(16):4773&#x02013;81.<pub-id pub-id-type="pmid">35793409</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>SY</given-names></name><name><surname>Shih</surname><given-names>YH</given-names></name><name><surname>Shieh</surname><given-names>TM</given-names></name><name><surname>Tseng</surname><given-names>YH</given-names></name></person-group><article-title>Proteasome inhibitors interrupt the activation of non-canonical NF-kappaB signaling pathway and induce cell apoptosis in cytarabine-resistant HL60 cells</article-title><source>Int J Mol Sci</source><year>2021</year><pub-id pub-id-type="doi">10.3390/ijms23010361</pub-id><pub-id pub-id-type="pmid">35008882</pub-id>
</element-citation><mixed-citation id="mc-CR60" publication-type="journal">Wang SY, Shih YH, Shieh TM, Tseng YH. Proteasome inhibitors interrupt the activation of non-canonical NF-kappaB signaling pathway and induce cell apoptosis in cytarabine-resistant HL60 cells. Int J Mol Sci. 2021. 10.3390/ijms23010361.<pub-id pub-id-type="pmid">35008882</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name><surname>Kubiczkova</surname><given-names>L</given-names></name><name><surname>Pour</surname><given-names>L</given-names></name><name><surname>Sedlarikova</surname><given-names>L</given-names></name><name><surname>Hajek</surname><given-names>R</given-names></name><name><surname>Sevcikova</surname><given-names>S</given-names></name></person-group><article-title>Proteasome inhibitors &#x02013; molecular basis and current perspectives in multiple myeloma</article-title><source>J Cell Mol Med</source><year>2014</year><volume>18</volume><issue>6</issue><fpage>947</fpage><lpage>961</lpage><pub-id pub-id-type="doi">10.1111/jcmm.12279</pub-id><pub-id pub-id-type="pmid">24712303</pub-id>
</element-citation><mixed-citation id="mc-CR61" publication-type="journal">Kubiczkova L, Pour L, Sedlarikova L, Hajek R, Sevcikova S. Proteasome inhibitors &#x02013; molecular basis and current perspectives in multiple myeloma. J Cell Mol Med. 2014;18(6):947&#x02013;61.<pub-id pub-id-type="pmid">24712303</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name><surname>Tundo</surname><given-names>GR</given-names></name><name><surname>Sbardella</surname><given-names>D</given-names></name><name><surname>Santoro</surname><given-names>AM</given-names></name><name><surname>Coletta</surname><given-names>A</given-names></name><name><surname>Oddone</surname><given-names>F</given-names></name><name><surname>Grasso</surname><given-names>G</given-names></name><etal/></person-group><article-title>The proteasome as a druggable target with multiple therapeutic potentialities: cutting and non-cutting edges</article-title><source>Pharmacol Therap</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.pharmthera.2020.107579</pub-id></element-citation><mixed-citation id="mc-CR62" publication-type="journal">Tundo GR, Sbardella D, Santoro AM, Coletta A, Oddone F, Grasso G, et al. The proteasome as a druggable target with multiple therapeutic potentialities: cutting and non-cutting edges. Pharmacol Therap. 2020. 10.1016/j.pharmthera.2020.107579.</mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name><surname>Melaccio</surname><given-names>A</given-names></name><name><surname>Reale</surname><given-names>A</given-names></name><name><surname>Saltarella</surname><given-names>I</given-names></name><name><surname>Desantis</surname><given-names>V</given-names></name><name><surname>Lamanuzzi</surname><given-names>A</given-names></name><name><surname>Cicco</surname><given-names>S</given-names></name><etal/></person-group><article-title>Pathways of angiogenic and inflammatory cytokines in multiple myeloma: role in plasma cell clonal expansion and drug resistance</article-title><source>J Clin Med</source><year>2022</year><pub-id pub-id-type="doi">10.3390/jcm11216491</pub-id><pub-id pub-id-type="pmid">36362718</pub-id>
</element-citation><mixed-citation id="mc-CR63" publication-type="journal">Melaccio A, Reale A, Saltarella I, Desantis V, Lamanuzzi A, Cicco S, et al. Pathways of angiogenic and inflammatory cytokines in multiple myeloma: role in plasma cell clonal expansion and drug resistance. J Clin Med. 2022. 10.3390/jcm11216491.<pub-id pub-id-type="pmid">36362718</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name><surname>Doumat</surname><given-names>G</given-names></name><name><surname>Daher</surname><given-names>D</given-names></name><name><surname>Zerdan</surname><given-names>MB</given-names></name><name><surname>Nasra</surname><given-names>N</given-names></name><name><surname>Bahmad</surname><given-names>HF</given-names></name><name><surname>Recine</surname><given-names>M</given-names></name><etal/></person-group><article-title>Drug repurposing in non-small cell lung carcinoma: old solutions for new problems</article-title><source>Curr Oncol</source><year>2023</year><volume>30</volume><issue>1</issue><fpage>704</fpage><lpage>719</lpage><pub-id pub-id-type="doi">10.3390/curroncol30010055</pub-id><pub-id pub-id-type="pmid">36661704</pub-id>
</element-citation><mixed-citation id="mc-CR64" publication-type="journal">Doumat G, Daher D, Zerdan MB, Nasra N, Bahmad HF, Recine M, et al. Drug repurposing in non-small cell lung carcinoma: old solutions for new problems. Curr Oncol. 2023;30(1):704&#x02013;19.<pub-id pub-id-type="pmid">36661704</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name><surname>Jayaweera</surname><given-names>SPE</given-names></name><name><surname>Wanigasinghe Kanakanamge</surname><given-names>SP</given-names></name><name><surname>Rajalingam</surname><given-names>D</given-names></name><name><surname>Silva</surname><given-names>GN</given-names></name></person-group><article-title>Carfilzomib: a promising proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma</article-title><source>Front Oncol</source><year>2021</year><volume>11</volume><fpage>740796</fpage><pub-id pub-id-type="doi">10.3389/fonc.2021.740796</pub-id><pub-id pub-id-type="pmid">34858819</pub-id>
</element-citation><mixed-citation id="mc-CR65" publication-type="journal">Jayaweera SPE, Wanigasinghe Kanakanamge SP, Rajalingam D, Silva GN. Carfilzomib: a promising proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma. Front Oncol. 2021;11: 740796.<pub-id pub-id-type="pmid">34858819</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><mixed-citation publication-type="other">Alvin TCL, Hawariah LPA, Tan AN. 2023 Styrylpyrone Derivative (SPD) induces apoptosis in a caspase-7-dependent manner in the human breast cancer cell line MCF-7. Cancer Cell International. 3(16).</mixed-citation></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name><surname>Kozalak</surname><given-names>G</given-names></name><name><surname>Butun</surname><given-names>I</given-names></name><name><surname>Toyran</surname><given-names>E</given-names></name><name><surname>Kosar</surname><given-names>A</given-names></name></person-group><article-title>Review on bortezomib resistance in multiple myeloma and potential role of emerging technologies</article-title><source>Pharmaceuticals (Basel)</source><year>2023</year><pub-id pub-id-type="doi">10.3390/ph16010111</pub-id><pub-id pub-id-type="pmid">36678608</pub-id>
</element-citation><mixed-citation id="mc-CR67" publication-type="journal">Kozalak G, Butun I, Toyran E, Kosar A. Review on bortezomib resistance in multiple myeloma and potential role of emerging technologies. Pharmaceuticals (Basel). 2023. 10.3390/ph16010111.<pub-id pub-id-type="pmid">36678608</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name><surname>Manzo</surname><given-names>A</given-names></name><name><surname>Montanino</surname><given-names>A</given-names></name><name><surname>Carillio</surname><given-names>G</given-names></name><name><surname>Costanzo</surname><given-names>R</given-names></name><name><surname>Sandomenico</surname><given-names>C</given-names></name><name><surname>Normanno</surname><given-names>N</given-names></name><etal/></person-group><article-title>Angiogenesis Inhibitors in NSCLC</article-title><source>Int J Mol Sci</source><year>2017</year><pub-id pub-id-type="doi">10.3390/ijms18102021</pub-id><pub-id pub-id-type="pmid">28934120</pub-id>
</element-citation><mixed-citation id="mc-CR68" publication-type="journal">Manzo A, Montanino A, Carillio G, Costanzo R, Sandomenico C, Normanno N, et al. Angiogenesis Inhibitors in NSCLC. Int J Mol Sci. 2017. 10.3390/ijms18102021.<pub-id pub-id-type="pmid">28934120</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name><surname>Genovese</surname><given-names>T</given-names></name><name><surname>Impellizzeri</surname><given-names>D</given-names></name><name><surname>D'Amico</surname><given-names>R</given-names></name><name><surname>Fusco</surname><given-names>R</given-names></name><name><surname>Peritore</surname><given-names>AF</given-names></name><name><surname>Di Paola</surname><given-names>D</given-names></name><etal/></person-group><article-title>Role of bevacizumab on vascular endothelial growth factor in apolipoprotein E deficient mice after traumatic brain injury</article-title><source>Int J Mol Sci</source><year>2022</year><pub-id pub-id-type="doi">10.3390/ijms23084162</pub-id><pub-id pub-id-type="pmid">36361691</pub-id>
</element-citation><mixed-citation id="mc-CR69" publication-type="journal">Genovese T, Impellizzeri D, D&#x02019;Amico R, Fusco R, Peritore AF, Di Paola D, et al. Role of bevacizumab on vascular endothelial growth factor in apolipoprotein E deficient mice after traumatic brain injury. Int J Mol Sci. 2022. 10.3390/ijms23084162.<pub-id pub-id-type="pmid">36361691</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>H</given-names></name><name><surname>Mahmud</surname><given-names>AR</given-names></name><name><surname>Siddiquee</surname><given-names>MF</given-names></name><name><surname>Shahriar</surname><given-names>A</given-names></name><name><surname>Biswas</surname><given-names>P</given-names></name><name><surname>Shimul</surname><given-names>MEK</given-names></name><etal/></person-group><article-title>Role of T cells in cancer immunotherapy: opportunities and challenges</article-title><source>Cancer Pathog Ther</source><year>2023</year><volume>1</volume><issue>2</issue><fpage>116</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1016/j.cpt.2022.12.002</pub-id><pub-id pub-id-type="pmid">38328405</pub-id>
</element-citation><mixed-citation id="mc-CR70" publication-type="journal">Ahmed H, Mahmud AR, Siddiquee MF, Shahriar A, Biswas P, Shimul MEK, et al. Role of T cells in cancer immunotherapy: opportunities and challenges. Cancer Pathog Ther. 2023;1(2):116&#x02013;26.<pub-id pub-id-type="pmid">38328405</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name><surname>Ost</surname><given-names>M</given-names></name><name><surname>Singh</surname><given-names>A</given-names></name><name><surname>Peschel</surname><given-names>A</given-names></name><name><surname>Mehling</surname><given-names>R</given-names></name><name><surname>Rieber</surname><given-names>N</given-names></name><name><surname>Hartl</surname><given-names>D</given-names></name></person-group><article-title>Myeloid-derived suppressor cells in bacterial infections</article-title><source>Front Cell Infect Microbiol</source><year>2016</year><volume>6</volume><fpage>37</fpage><pub-id pub-id-type="doi">10.3389/fcimb.2016.00037</pub-id><pub-id pub-id-type="pmid">27066459</pub-id>
</element-citation><mixed-citation id="mc-CR71" publication-type="journal">Ost M, Singh A, Peschel A, Mehling R, Rieber N, Hartl D. Myeloid-derived suppressor cells in bacterial infections. Front Cell Infect Microbiol. 2016;6:37.<pub-id pub-id-type="pmid">27066459</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name><surname>Bayati</surname><given-names>F</given-names></name><name><surname>Mohammadi</surname><given-names>M</given-names></name><name><surname>Valadi</surname><given-names>M</given-names></name><name><surname>Jamshidi</surname><given-names>S</given-names></name><name><surname>Foma</surname><given-names>AM</given-names></name><name><surname>Sharif-Paghaleh</surname><given-names>E</given-names></name></person-group><article-title>The therapeutic potential of regulatory T cells: challenges and opportunities</article-title><source>Front Immunol</source><year>2020</year><volume>11</volume><fpage>585819</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.585819</pub-id><pub-id pub-id-type="pmid">33519807</pub-id>
</element-citation><mixed-citation id="mc-CR72" publication-type="journal">Bayati F, Mohammadi M, Valadi M, Jamshidi S, Foma AM, Sharif-Paghaleh E. The therapeutic potential of regulatory T cells: challenges and opportunities. Front Immunol. 2020;11: 585819.<pub-id pub-id-type="pmid">33519807</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Hang</surname><given-names>S</given-names></name><name><surname>Fang</surname><given-names>Y</given-names></name><name><surname>Bae</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><etal/></person-group><article-title>A bacterial bile acid metabolite modulates T(reg) activity through the nuclear hormone receptor NR4A1</article-title><source>Cell Host Microbe</source><year>2021</year><volume>29</volume><issue>9</issue><fpage>1366</fpage><lpage>1377</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2021.07.013</pub-id><pub-id pub-id-type="pmid">34416161</pub-id>
</element-citation><mixed-citation id="mc-CR73" publication-type="journal">Li W, Hang S, Fang Y, Bae S, Zhang Y, Zhang M, et al. A bacterial bile acid metabolite modulates T(reg) activity through the nuclear hormone receptor NR4A1. Cell Host Microbe. 2021;29(9):1366&#x02013;77.<pub-id pub-id-type="pmid">34416161</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><mixed-citation publication-type="other">Rahman M, Bordoni B. 2023 Histology, Natural Killer Cells. . StatPearls, editor. Treasure Island StatPearls Publishing.</mixed-citation></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name><surname>Owens</surname><given-names>JA</given-names></name><name><surname>Saeedi</surname><given-names>BJ</given-names></name><name><surname>Naudin</surname><given-names>CR</given-names></name><name><surname>Hunter-Chang</surname><given-names>S</given-names></name><name><surname>Barbian</surname><given-names>ME</given-names></name><name><surname>Eboka</surname><given-names>RU</given-names></name><etal/></person-group><article-title>Lactobacillus rhamnosus GG Orchestrates an antitumor immune response</article-title><source>Cell Mol Gastroenterol Hepatol</source><year>2021</year><volume>12</volume><issue>4</issue><fpage>1311</fpage><lpage>1327</lpage><pub-id pub-id-type="doi">10.1016/j.jcmgh.2021.06.001</pub-id><pub-id pub-id-type="pmid">34111601</pub-id>
</element-citation><mixed-citation id="mc-CR75" publication-type="journal">Owens JA, Saeedi BJ, Naudin CR, Hunter-Chang S, Barbian ME, Eboka RU, et al. Lactobacillus rhamnosus GG Orchestrates an antitumor immune response. Cell Mol Gastroenterol Hepatol. 2021;12(4):1311&#x02013;27.<pub-id pub-id-type="pmid">34111601</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name><surname>Greathouse</surname><given-names>KL</given-names></name><name><surname>Choudhury</surname><given-names>A</given-names></name></person-group><article-title>Spiking immunotherapy with a bacterial cocktail brings T cells back to the fight</article-title><source>Cell Rep Med</source><year>2021</year><volume>2</volume><issue>10</issue><fpage>100430</fpage><pub-id pub-id-type="doi">10.1016/j.xcrm.2021.100430</pub-id><pub-id pub-id-type="pmid">34755141</pub-id>
</element-citation><mixed-citation id="mc-CR76" publication-type="journal">Greathouse KL, Choudhury A. Spiking immunotherapy with a bacterial cocktail brings T cells back to the fight. Cell Rep Med. 2021;2(10): 100430.<pub-id pub-id-type="pmid">34755141</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name><surname>Boucher</surname><given-names>E</given-names></name><name><surname>Plazy</surname><given-names>C</given-names></name><name><surname>Richard</surname><given-names>ML</given-names></name><name><surname>Suau</surname><given-names>A</given-names></name><name><surname>Mangin</surname><given-names>I</given-names></name><name><surname>Cornet</surname><given-names>M</given-names></name><etal/></person-group><article-title>Inulin prebiotic reinforces host cancer immunosurveillance via &#x00263;delta T cell activation</article-title><source>Front Immunol</source><year>2023</year><volume>14</volume><fpage>1104224</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2023.1104224</pub-id><pub-id pub-id-type="pmid">36875124</pub-id>
</element-citation><mixed-citation id="mc-CR77" publication-type="journal">Boucher E, Plazy C, Richard ML, Suau A, Mangin I, Cornet M, et al. Inulin prebiotic reinforces host cancer immunosurveillance via &#x00263;delta T cell activation. Front Immunol. 2023;14:1104224.<pub-id pub-id-type="pmid">36875124</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name><surname>Fantini</surname><given-names>M</given-names></name><name><surname>Arlen</surname><given-names>PM</given-names></name><name><surname>Tsang</surname><given-names>KY</given-names></name></person-group><article-title>Potentiation of natural killer cells to overcome cancer resistance to NK cell-based therapy and to enhance antibody-based immunotherapy</article-title><source>Front Immunol</source><year>2023</year><volume>14</volume><fpage>1275904</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2023.1275904</pub-id><pub-id pub-id-type="pmid">38077389</pub-id>
</element-citation><mixed-citation id="mc-CR78" publication-type="journal">Fantini M, Arlen PM, Tsang KY. Potentiation of natural killer cells to overcome cancer resistance to NK cell-based therapy and to enhance antibody-based immunotherapy. Front Immunol. 2023;14:1275904.<pub-id pub-id-type="pmid">38077389</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR79"><label>79.</label><citation-alternatives><element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name></person-group><article-title>Tumor-associated macrophages in tumor immunity</article-title><source>Front Immunol</source><year>2020</year><volume>11</volume><fpage>583084</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.583084</pub-id><pub-id pub-id-type="pmid">33365025</pub-id>
</element-citation><mixed-citation id="mc-CR79" publication-type="journal">Pan Y, Yu Y, Wang X, Zhang T. Tumor-associated macrophages in tumor immunity. Front Immunol. 2020;11: 583084.<pub-id pub-id-type="pmid">33365025</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR80"><label>80.</label><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Song</surname><given-names>Y</given-names></name><name><surname>Du</surname><given-names>W</given-names></name><name><surname>Gong</surname><given-names>L</given-names></name><name><surname>Chang</surname><given-names>H</given-names></name><name><surname>Zou</surname><given-names>Z</given-names></name></person-group><article-title>Tumor-associated macrophages: an accomplice in solid tumor progression</article-title><source>J Biomed Sci</source><year>2019</year><volume>26</volume><issue>1</issue><fpage>78</fpage><pub-id pub-id-type="doi">10.1186/s12929-019-0568-z</pub-id><pub-id pub-id-type="pmid">31629410</pub-id>
</element-citation><mixed-citation id="mc-CR80" publication-type="journal">Chen Y, Song Y, Du W, Gong L, Chang H, Zou Z. Tumor-associated macrophages: an accomplice in solid tumor progression. J Biomed Sci. 2019;26(1):78.<pub-id pub-id-type="pmid">31629410</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR81"><label>81.</label><citation-alternatives><element-citation id="ec-CR81" publication-type="journal"><person-group person-group-type="author"><name><surname>Apte</surname><given-names>RS</given-names></name><name><surname>Chen</surname><given-names>DS</given-names></name><name><surname>Ferrara</surname><given-names>N</given-names></name></person-group><article-title>VEGF in signaling and disease: beyond discovery and development</article-title><source>Cell</source><year>2019</year><volume>176</volume><issue>6</issue><fpage>1248</fpage><lpage>1264</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.01.021</pub-id><pub-id pub-id-type="pmid">30849371</pub-id>
</element-citation><mixed-citation id="mc-CR81" publication-type="journal">Apte RS, Chen DS, Ferrara N. VEGF in signaling and disease: beyond discovery and development. Cell. 2019;176(6):1248&#x02013;64.<pub-id pub-id-type="pmid">30849371</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>